{
 "disease": "diffuse-large-b-cell-lymphoma",
 "label": "Diffuse large B-cell lymphoma",
 "url": "https://usebiotransfer.org/disease/diffuse-large-b-cell-lymphoma/",
 "built": "2026-09-12",
 "facts_hash": {
  "answers": "a4232dfcf575",
  "targets": "39b446aae7fc"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-12",
  "trials": "2026-09-12"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "MS4A1",
   "ensembl": "ENSG00000156738",
   "n_drug_entries": 18,
   "n_distinct_drugs": 18,
   "drugs": {
    "EPCORITAMAB": "APPROVAL",
    "FBT-A05": "PHASE_1_2",
    "GLOFITAMAB": "APPROVAL",
    "LFB-R603": "PHASE_1",
    "MOSUNETUZUMAB": "APPROVAL",
    "MT-3724": "PHASE_2",
    "OBINUTUZUMAB": "APPROVAL",
    "OCARATUZUMAB": "PHASE_2",
    "OCRELIZUMAB": "APPROVAL",
    "ODRONEXTAMAB": "APPROVAL",
    "OFATUMUMAB": "APPROVAL",
    "RITUXIMAB": "APPROVAL",
    "TOSITUMOMAB": "APPROVAL",
    "TOSITUMOMAB 131I": "PHASE_3",
    "TRU-015": "PHASE_2",
    "UBLITUXIMAB": "APPROVAL",
    "VELTUZUMAB": "PHASE_2",
    "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": "APPROVAL"
   },
   "approved": [
    "EPCORITAMAB",
    "GLOFITAMAB",
    "MOSUNETUZUMAB",
    "OBINUTUZUMAB",
    "OCRELIZUMAB",
    "ODRONEXTAMAB",
    "OFATUMUMAB",
    "RITUXIMAB",
    "TOSITUMOMAB",
    "UBLITUXIMAB",
    "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN"
   ],
   "n_approved": 11,
   "approved_for": {
    "EPCORITAMAB": [
     "follicular lymphoma",
     "B-cell non-Hodgkin lymphoma",
     "diffuse large B-cell lymphoma"
    ],
    "GLOFITAMAB": [
     "diffuse large B-cell lymphoma"
    ],
    "MOSUNETUZUMAB": [
     "follicular lymphoma"
    ],
    "OBINUTUZUMAB": [
     "follicular lymphoma",
     "B-cell chronic lymphocytic leukemia"
    ],
    "OCRELIZUMAB": [
     "multiple sclerosis",
     "diffuse large B-cell lymphoma",
     "relapsing-remitting multiple sclerosis",
     "chronic progressive multiple sclerosis"
    ],
    "ODRONEXTAMAB": [
     "follicular lymphoma"
    ],
    "OFATUMUMAB": [
     "relapsing-remitting multiple sclerosis",
     "B-cell chronic lymphocytic leukemia",
     "multiple sclerosis",
     "secondary progressive multiple sclerosis"
    ],
    "RITUXIMAB": [
     "non-Hodgkin lymphoma",
     "granulomatosis with polyangiitis",
     "B-cell chronic lymphocytic leukemia",
     "acute lymphoblastic leukemia",
     "rheumatoid arthritis",
     "microscopic polyangiitis",
     "pemphigus",
     "vasculitis"
    ],
    "TOSITUMOMAB": [
     "non-Hodgkin lymphoma"
    ],
    "UBLITUXIMAB": [
     "multiple sclerosis",
     "relapsing-remitting multiple sclerosis",
     "chronic progressive multiple sclerosis"
    ],
    "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": [
     "follicular lymphoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "CD19",
   "ensembl": "ENSG00000177455",
   "n_drug_entries": 14,
   "n_distinct_drugs": 14,
   "drugs": {
    "AXICABTAGENE CILOLEUCEL": "APPROVAL",
    "BLINATUMOMAB": "APPROVAL",
    "BREXUCABTAGENE AUTOLEUCEL": "APPROVAL",
    "COLTUXIMAB RAVTANSINE": "PHASE_2",
    "DENINTUZUMAB MAFODOTIN": "PHASE_2",
    "INEBILIZUMAB": "APPROVAL",
    "LISOCABTAGENE MARALEUCEL": "APPROVAL",
    "LONCASTUXIMAB TESIRINE": "APPROVAL",
    "MDX-1342": "PHASE_2",
    "OBECABTAGENE AUTOLEUCEL": "APPROVAL",
    "OBEXELIMAB": "PHASE_3",
    "ONCOLYSIN B": "PHASE_2",
    "TAFASITAMAB": "APPROVAL",
    "TISAGENLECLEUCEL": "APPROVAL"
   },
   "approved": [
    "AXICABTAGENE CILOLEUCEL",
    "BLINATUMOMAB",
    "BREXUCABTAGENE AUTOLEUCEL",
    "INEBILIZUMAB",
    "LISOCABTAGENE MARALEUCEL",
    "LONCASTUXIMAB TESIRINE",
    "OBECABTAGENE AUTOLEUCEL",
    "TAFASITAMAB",
    "TISAGENLECLEUCEL"
   ],
   "n_approved": 9,
   "approved_for": {
    "AXICABTAGENE CILOLEUCEL": [
     "diffuse large B-cell lymphoma",
     "follicular lymphoma"
    ],
    "BLINATUMOMAB": [
     "acute lymphoblastic leukemia",
     "B-cell acute lymphoblastic leukemia",
     "lymphoid leukemia"
    ],
    "BREXUCABTAGENE AUTOLEUCEL": [
     "mantle cell lymphoma"
    ],
    "INEBILIZUMAB": [
     "neuromyelitis optica"
    ],
    "LISOCABTAGENE MARALEUCEL": [
     "diffuse large B-cell lymphoma",
     "follicular lymphoma",
     "neoplasm of mediastinum"
    ],
    "LONCASTUXIMAB TESIRINE": [
     "diffuse large B-cell lymphoma",
     "B-cell neoplasm",
     "B-cell non-Hodgkin lymphoma"
    ],
    "OBECABTAGENE AUTOLEUCEL": [
     "B-cell acute lymphoblastic leukemia"
    ],
    "TAFASITAMAB": [
     "diffuse large B-cell lymphoma",
     "lymphoma"
    ],
    "TISAGENLECLEUCEL": [
     "diffuse large B-cell lymphoma"
    ]
   },
   "tractability": [
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "CD79B",
   "ensembl": "ENSG00000007312",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "POLATUZUMAB VEDOTIN": "APPROVAL"
   },
   "approved": [
    "POLATUZUMAB VEDOTIN"
   ],
   "n_approved": 1,
   "approved_for": {
    "POLATUZUMAB VEDOTIN": [
     "diffuse large B-cell lymphoma",
     "B-cell non-Hodgkin lymphoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "BCL2",
   "ensembl": "ENSG00000171791",
   "n_drug_entries": 7,
   "n_distinct_drugs": 5,
   "drugs": {
    "APG-2575": "PHASE_3",
    "NAVITOCLAX": "APPROVAL",
    "OBATOCLAX": "PHASE_3",
    "OBLIMERSEN": "APPROVAL",
    "VENETOCLAX": "APPROVAL"
   },
   "approved": [
    "NAVITOCLAX",
    "OBLIMERSEN",
    "VENETOCLAX"
   ],
   "n_approved": 3,
   "approved_for": {
    "NAVITOCLAX": [],
    "OBLIMERSEN": [],
    "VENETOCLAX": [
     "B-cell chronic lymphocytic leukemia"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "BCL6",
   "ensembl": "ENSG00000113916",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "MYC",
   "ensembl": "ENSG00000136997",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "EZH2",
   "ensembl": "ENSG00000106462",
   "n_drug_entries": 3,
   "n_distinct_drugs": 3,
   "drugs": {
    "GSK2816126": "PHASE_1",
    "TAZEMETOSTAT": "APPROVAL",
    "TAZEMETOSTAT HYDROBROMIDE": "APPROVAL"
   },
   "approved": [
    "TAZEMETOSTAT",
    "TAZEMETOSTAT HYDROBROMIDE"
   ],
   "n_approved": 2,
   "approved_for": {
    "TAZEMETOSTAT": [
     "follicular lymphoma"
    ],
    "TAZEMETOSTAT HYDROBROMIDE": [
     "follicular lymphoma",
     "sarcoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "MYD88",
   "ensembl": "ENSG00000172936",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "CREBBP",
   "ensembl": "ENSG00000005339",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "PRI-724": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "KMT2D",
   "ensembl": "ENSG00000167548",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "BTK",
   "ensembl": "ENSG00000010671",
   "n_drug_entries": 24,
   "n_distinct_drugs": 20,
   "drugs": {
    "ABIVERTINIB": "PHASE_3",
    "ACALABRUTINIB": "APPROVAL",
    "BMS-986142": "PHASE_2",
    "BRANEBRUTINIB": "PHASE_2",
    "EDRALBRUTINIB": "PHASE_2",
    "ELSUBRUTINIB": "PHASE_2",
    "EVOBRUTINIB": "PHASE_3",
    "FENEBRUTINIB": "PHASE_3",
    "IBRUTINIB": "APPROVAL",
    "MSC-2364447": "PHASE_1",
    "ORELABRUTINIB": "APPROVAL",
    "PIRTOBRUTINIB": "APPROVAL",
    "POSELTINIB": "PHASE_2",
    "RILZABRUTINIB": "APPROVAL",
    "RITLECITINIB": "APPROVAL",
    "SPEBRUTINIB": "PHASE_2",
    "TIRABRUTINIB": "APPROVAL",
    "TOLEBRUTINIB": "PREAPPROVAL",
    "VECABRUTINIB": "PHASE_1_2",
    "ZANUBRUTINIB": "APPROVAL"
   },
   "approved": [
    "ACALABRUTINIB",
    "IBRUTINIB",
    "ORELABRUTINIB",
    "PIRTOBRUTINIB",
    "RILZABRUTINIB",
    "RITLECITINIB",
    "TIRABRUTINIB",
    "ZANUBRUTINIB"
   ],
   "n_approved": 8,
   "approved_for": {
    "ACALABRUTINIB": [
     "B-cell chronic lymphocytic leukemia",
     "childhood leukemia",
     "mantle cell lymphoma"
    ],
    "IBRUTINIB": [
     "macroglobulinemia",
     "mantle cell lymphoma",
     "B-cell chronic lymphocytic leukemia"
    ],
    "ORELABRUTINIB": [],
    "PIRTOBRUTINIB": [
     "mantle cell lymphoma",
     "non-Hodgkin lymphoma"
    ],
    "RILZABRUTINIB": [
     "autoimmune thrombocytopenic purpura"
    ],
    "RITLECITINIB": [
     "alopecia areata"
    ],
    "TIRABRUTINIB": [],
    "ZANUBRUTINIB": [
     "mantle cell lymphoma",
     "B-cell chronic lymphocytic leukemia",
     "lymphoplasmacytic lymphoma",
     "Waldenstrom macroglobulinemia"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Phase 1 Clinical"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "CD19": {
    "n": 216,
    "n_observational": 25,
    "n_active": 109,
    "n_withdrawn": 9,
    "trials": [
     {
      "nct": "NCT03676504",
      "title": "Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR",
      "status": "RECRUITING",
      "last_update": "2024-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04094311",
      "title": "Study of Out of Specification for Tisagenlecleucel",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04186520",
      "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04512716",
      "title": "Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04545762",
      "title": "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04792489",
      "title": "DALY II USA/ MB-CART2019.1 for DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04830137",
      "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04836507",
      "title": "Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04844866",
      "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04889716",
      "title": "CAR-T Followed by Bispecific Antibodies",
      "status": "RECRUITING",
      "last_update": "2026-05-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05052528",
      "title": "Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05077527",
      "title": "Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05281809",
      "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05326243",
      "title": "Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05365659",
      "title": "IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05432635",
      "title": "Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05514327",
      "title": "A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05552937",
      "title": "Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL",
      "status": "RECRUITING",
      "last_update": "2022-09-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05600686",
      "title": "Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05633615",
      "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05641428",
      "title": "Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL",
      "status": "RECRUITING",
      "last_update": "2024-09-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05659628",
      "title": "CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL",
      "status": "RECRUITING",
      "last_update": "2022-12-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05672251",
      "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05757219",
      "title": "Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05826535",
      "title": "Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05873712",
      "title": "Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome",
      "status": "RECRUITING",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05890352",
      "title": "Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment",
      "status": "RECRUITING",
      "last_update": "2025-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05950802",
      "title": "Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta",
      "status": "RECRUITING",
      "last_update": "2025-12-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06026319",
      "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06045910",
      "title": "A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-07-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047197",
      "title": "Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06081478",
      "title": "CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2023-10-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06120166",
      "title": "Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research",
      "status": "RECRUITING",
      "last_update": "2025-09-19",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06213636",
      "title": "Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).",
      "status": "RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06227026",
      "title": "Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06238648",
      "title": "Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy",
      "status": "RECRUITING",
      "last_update": "2024-09-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06464861",
      "title": "Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-02-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06486051",
      "title": "A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06500273",
      "title": "Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06517004",
      "title": "An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06521255",
      "title": "Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-07-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06528301",
      "title": "A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06533579",
      "title": "Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06544265",
      "title": "SynKIR-310 for Relapsed/Refractory B-NHL",
      "status": "RECRUITING",
      "last_update": "2026-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06550141",
      "title": "Emapalumab Prevention of CAR-T Cell Associated Toxicities",
      "status": "RECRUITING",
      "last_update": "2025-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06768905",
      "title": "IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06830031",
      "title": "Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06902012",
      "title": "Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-03-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06918912",
      "title": "Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure",
      "status": "RECRUITING",
      "last_update": "2025-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06977711",
      "title": "Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Na\u00efve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07042438",
      "title": "Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells",
      "status": "RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07077512",
      "title": "Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07126236",
      "title": "Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07188558",
      "title": "A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07197307",
      "title": "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07225439",
      "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07254754",
      "title": "Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07260812",
      "title": "KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07284433",
      "title": "Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07288879",
      "title": "DALY II Japan/MB-CART2019.1 for DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07368270",
      "title": "Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07473167",
      "title": "Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients",
      "status": "RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07478848",
      "title": "Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07502118",
      "title": "NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)",
      "status": "RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07548697",
      "title": "A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07788118",
      "title": "A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7\u00d719-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003874",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00889408",
      "title": "DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00924326",
      "title": "CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-01-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01029366",
      "title": "CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2023-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01453205",
      "title": "A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2018-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01470456",
      "title": "Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01472887",
      "title": "SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients",
      "status": "COMPLETED",
      "last_update": "2018-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01475058",
      "title": "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant",
      "status": "COMPLETED",
      "last_update": "2017-02-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01497184",
      "title": "Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood",
      "status": "COMPLETED",
      "last_update": "2025-03-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01741792",
      "title": "Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2017-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01786135",
      "title": "A Safety Study of SGN-CD19A for B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01815749",
      "title": "Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01864889",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19",
      "status": "UNKNOWN",
      "last_update": "2016-01-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01865617",
      "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-05-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02051257",
      "title": "Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02134262",
      "title": "Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes",
      "status": "UNKNOWN",
      "last_update": "2014-11-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02153580",
      "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02274506",
      "title": "Infusion of Allogeneic, 3rd Party CD19-specific T Cells",
      "status": "WITHDRAWN",
      "last_update": "2020-01-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02348216",
      "title": "Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02374333",
      "title": "Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy",
      "status": "COMPLETED",
      "last_update": "2021-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02399085",
      "title": "Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL",
      "status": "COMPLETED",
      "last_update": "2023-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02431988",
      "title": "Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation",
      "status": "COMPLETED",
      "last_update": "2023-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02445248",
      "title": "Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients",
      "status": "COMPLETED",
      "last_update": "2024-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02454270",
      "title": "A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2018-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02568553",
      "title": "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-11-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02592876",
      "title": "Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02631044",
      "title": "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)",
      "status": "COMPLETED",
      "last_update": "2024-06-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02650999",
      "title": "Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas",
      "status": "COMPLETED",
      "last_update": "2021-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02652910",
      "title": "Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2019-02-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02669017",
      "title": "Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)",
      "status": "COMPLETED",
      "last_update": "2021-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02685670",
      "title": "Competitive Transfer of \u03b1CD19-TCRz-CD28 and \u03b1CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2017-03-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02702141",
      "title": "A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02706405",
      "title": "JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2022-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02721407",
      "title": "Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients",
      "status": "UNKNOWN",
      "last_update": "2017-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02728882",
      "title": "Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2017-03-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02737085",
      "title": "the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)",
      "status": "UNKNOWN",
      "last_update": "2016-09-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02763319",
      "title": "A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2025-07-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02819583",
      "title": "CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-10-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02846584",
      "title": "a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2016-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02851589",
      "title": "Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-08-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02855359",
      "title": "Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02892695",
      "title": "PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-12-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02926833",
      "title": "Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2024-03-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02976857",
      "title": "A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects",
      "status": "COMPLETED",
      "last_update": "2019-01-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03097770",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20",
      "status": "COMPLETED",
      "last_update": "2020-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03103971",
      "title": "huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2024-04-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03185494",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22",
      "status": "UNKNOWN",
      "last_update": "2019-04-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03287817",
      "title": "Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-07-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03391466",
      "title": "Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-12-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03483103",
      "title": "Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)",
      "status": "COMPLETED",
      "last_update": "2023-12-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03484702",
      "title": "Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-12-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03570892",
      "title": "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-06-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03571828",
      "title": "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-03-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03579888",
      "title": "CD19-Specific T Cells Post AlloSCT",
      "status": "TERMINATED",
      "last_update": "2021-06-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03589469",
      "title": "Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03610724",
      "title": "Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2024-06-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03630159",
      "title": "Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2022-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684694",
      "title": "Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03685344",
      "title": "Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma",
      "status": "TERMINATED",
      "last_update": "2021-10-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03720457",
      "title": "Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.",
      "status": "UNKNOWN",
      "last_update": "2021-08-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03744676",
      "title": "A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)",
      "status": "COMPLETED",
      "last_update": "2025-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03876028",
      "title": "Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients",
      "status": "TERMINATED",
      "last_update": "2023-01-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03954106",
      "title": "A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity",
      "status": "TERMINATED",
      "last_update": "2021-12-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04007029",
      "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04026100",
      "title": "CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2019-10-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04049513",
      "title": "ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04052061",
      "title": "QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2025-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04067414",
      "title": "Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04089215",
      "title": "CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-11-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04134936",
      "title": "Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL",
      "status": "COMPLETED",
      "last_update": "2024-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04205838",
      "title": "Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04215016",
      "title": "Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2020-01-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04231747",
      "title": "A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04257578",
      "title": "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04271410",
      "title": "CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-04-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04316624",
      "title": "A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy",
      "status": "COMPLETED",
      "last_update": "2026-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04381741",
      "title": "CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-02-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04384484",
      "title": "Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04432506",
      "title": "Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04450069",
      "title": "CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04456023",
      "title": "Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)",
      "status": "WITHDRAWN",
      "last_update": "2022-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464200",
      "title": "19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04486872",
      "title": "An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection",
      "status": "UNKNOWN",
      "last_update": "2020-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04488354",
      "title": "Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T",
      "status": "COMPLETED",
      "last_update": "2026-04-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04594642",
      "title": "A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04607772",
      "title": "Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "WITHDRAWN",
      "last_update": "2025-10-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04661007",
      "title": "To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04726787",
      "title": "RadiothErapy priMIng for CAR-T",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-09",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04745559",
      "title": "Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04787263",
      "title": "CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04812691",
      "title": "CD19-targeted CAR T Cells \uff08JWCAR029\uff09 for Primary Refractory Diffuse Large B Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04824092",
      "title": "Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04844086",
      "title": "RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies",
      "status": "TERMINATED",
      "last_update": "2022-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04855253",
      "title": "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL",
      "status": "SUSPENDED",
      "last_update": "2026-01-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04890236",
      "title": "Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study",
      "status": "COMPLETED",
      "last_update": "2025-01-20",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04974216",
      "title": "Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04974996",
      "title": "A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)",
      "status": "WITHDRAWN",
      "last_update": "2022-03-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04978584",
      "title": "Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05020392",
      "title": "Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-07-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05075603",
      "title": "Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy",
      "status": "COMPLETED",
      "last_update": "2026-08-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05108805",
      "title": "Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting",
      "status": "COMPLETED",
      "last_update": "2025-03-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05144009",
      "title": "A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2025-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05199961",
      "title": "Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel",
      "status": "TERMINATED",
      "last_update": "2023-05-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05222438",
      "title": "Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant",
      "status": "WITHDRAWN",
      "last_update": "2023-11-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05222555",
      "title": "Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05228249",
      "title": "Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2023-01-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05269914",
      "title": "Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL",
      "status": "UNKNOWN",
      "last_update": "2022-03-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05328102",
      "title": "Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2024-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05336409",
      "title": "A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05359211",
      "title": "NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05404048",
      "title": "PD-L1 PET-imaging During CAR T-cell Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05421663",
      "title": "A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429268",
      "title": "Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05453396",
      "title": "Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2026-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05455697",
      "title": "Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05487651",
      "title": "Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2023-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05583149",
      "title": "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05621096",
      "title": "Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05626322",
      "title": "Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-09-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05658562",
      "title": "A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05660395",
      "title": "A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)",
      "status": "TERMINATED",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05664217",
      "title": "NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-02-13",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665062",
      "title": "Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05673447",
      "title": "The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-08-28",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05675982",
      "title": "Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05715606",
      "title": "Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research",
      "status": "UNKNOWN",
      "last_update": "2023-07-05",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05821088",
      "title": "Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05878184",
      "title": "Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05972720",
      "title": "A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06003179",
      "title": "Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah",
      "status": "WITHDRAWN",
      "last_update": "2024-11-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06093841",
      "title": "Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06149169",
      "title": "CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2024-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06256484",
      "title": "A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-03-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06343376",
      "title": "Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06552572",
      "title": "Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06561425",
      "title": "A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-06-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06827782",
      "title": "Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2025-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07024147",
      "title": "JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07030699",
      "title": "A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07098364",
      "title": "ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma",
      "status": "SUSPENDED",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07113496",
      "title": "RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07168291",
      "title": "Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07326371",
      "title": "Glofitamab Combined With CAR-T Therapy in R/R DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07412405",
      "title": "This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07502872",
      "title": "TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07503353",
      "title": "A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07621406",
      "title": "Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07676877",
      "title": "Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07713459",
      "title": "A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07725406",
      "title": "Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 108,
     "n_observational": 7,
     "n_active": 57,
     "n_withdrawn": 2,
     "trials": [
      {
       "nct": "NCT03676504",
       "title": "Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR",
       "status": "RECRUITING",
       "last_update": "2024-07-29",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04186520",
       "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-02-23",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04512716",
       "title": "Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-02-17",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04545762",
       "title": "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-06-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04792489",
       "title": "DALY II USA/ MB-CART2019.1 for DLBCL",
       "status": "RECRUITING",
       "last_update": "2026-07-13",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04844866",
       "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients",
       "status": "RECRUITING",
       "last_update": "2026-06-10",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04889716",
       "title": "CAR-T Followed by Bispecific Antibodies",
       "status": "RECRUITING",
       "last_update": "2026-05-26",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05052528",
       "title": "Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-07-17",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05077527",
       "title": "Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-07-10",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05281809",
       "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2025-01-13",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05326243",
       "title": "Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2025-05-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05432635",
       "title": "Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-02-23",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05514327",
       "title": "A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL",
       "status": "RECRUITING",
       "last_update": "2026-03-24",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05633615",
       "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-02-02",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05641428",
       "title": "Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL",
       "status": "RECRUITING",
       "last_update": "2024-09-23",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05659628",
       "title": "CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL",
       "status": "RECRUITING",
       "last_update": "2022-12-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05757219",
       "title": "Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy",
       "status": "RECRUITING",
       "last_update": "2026-03-31",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05950802",
       "title": "Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta",
       "status": "RECRUITING",
       "last_update": "2025-12-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06026319",
       "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-03-16",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06081478",
       "title": "CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2023-10-13",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06120166",
       "title": "Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research",
       "status": "RECRUITING",
       "last_update": "2025-09-19",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06213636",
       "title": "Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).",
       "status": "RECRUITING",
       "last_update": "2025-08-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06227026",
       "title": "Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06238648",
       "title": "Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy",
       "status": "RECRUITING",
       "last_update": "2024-09-26",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06464861",
       "title": "Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2025-02-07",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06486051",
       "title": "A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-08-07",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06550141",
       "title": "Emapalumab Prevention of CAR-T Cell Associated Toxicities",
       "status": "RECRUITING",
       "last_update": "2025-11-14",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06768905",
       "title": "IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL",
       "status": "RECRUITING",
       "last_update": "2026-05-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06830031",
       "title": "Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-09-11",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06918912",
       "title": "Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure",
       "status": "RECRUITING",
       "last_update": "2025-04-09",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07042438",
       "title": "Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells",
       "status": "RECRUITING",
       "last_update": "2026-03-05",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07188558",
       "title": "A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",
       "status": "RECRUITING",
       "last_update": "2026-08-04",
       "phase": "PHASE3",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07225439",
       "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
       "status": "RECRUITING",
       "last_update": "2026-09-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07284433",
       "title": "Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-08-28",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07288879",
       "title": "DALY II Japan/MB-CART2019.1 for DLBCL",
       "status": "RECRUITING",
       "last_update": "2026-01-08",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07368270",
       "title": "Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-01-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07478848",
       "title": "Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas",
       "status": "RECRUITING",
       "last_update": "2026-07-01",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07788118",
       "title": "A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7\u00d719-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00924326",
       "title": "CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma",
       "status": "COMPLETED",
       "last_update": "2022-01-12",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01029366",
       "title": "CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy",
       "status": "COMPLETED",
       "last_update": "2023-06-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01475058",
       "title": "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant",
       "status": "COMPLETED",
       "last_update": "2017-02-15",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01497184",
       "title": "Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood",
       "status": "COMPLETED",
       "last_update": "2025-03-13",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01864889",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19",
       "status": "UNKNOWN",
       "last_update": "2016-01-28",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01865617",
       "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",
       "status": "COMPLETED",
       "last_update": "2022-05-25",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02051257",
       "title": "Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-03-31",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02134262",
       "title": "Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes",
       "status": "UNKNOWN",
       "last_update": "2014-11-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02153580",
       "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-10-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02274506",
       "title": "Infusion of Allogeneic, 3rd Party CD19-specific T Cells",
       "status": "WITHDRAWN",
       "last_update": "2020-01-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02374333",
       "title": "Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy",
       "status": "COMPLETED",
       "last_update": "2021-09-23",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02431988",
       "title": "Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation",
       "status": "COMPLETED",
       "last_update": "2023-04-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02650999",
       "title": "Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas",
       "status": "COMPLETED",
       "last_update": "2021-07-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02652910",
       "title": "Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2019-02-27",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02685670",
       "title": "Competitive Transfer of \u03b1CD19-TCRz-CD28 and \u03b1CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2017-03-16",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02721407",
       "title": "Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients",
       "status": "UNKNOWN",
       "last_update": "2017-03-10",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02728882",
       "title": "Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2017-03-23",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02737085",
       "title": "the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)",
       "status": "UNKNOWN",
       "last_update": "2016-09-07",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02819583",
       "title": "CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2016-10-25",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02846584",
       "title": "a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies",
       "status": "UNKNOWN",
       "last_update": "2016-09-07",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03097770",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20",
       "status": "COMPLETED",
       "last_update": "2020-09-02",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03103971",
       "title": "huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",
       "status": "TERMINATED",
       "last_update": "2024-04-10",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03185494",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22",
       "status": "UNKNOWN",
       "last_update": "2019-04-17",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03287817",
       "title": "Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma",
       "status": "TERMINATED",
       "last_update": "2025-07-14",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03579888",
       "title": "CD19-Specific T Cells Post AlloSCT",
       "status": "TERMINATED",
       "last_update": "2021-06-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03720457",
       "title": "Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.",
       "status": "UNKNOWN",
       "last_update": "2021-08-31",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03954106",
       "title": "A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity",
       "status": "TERMINATED",
       "last_update": "2021-12-09",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04007029",
       "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04049513",
       "title": "ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2024-08-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04067414",
       "title": "Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma",
       "status": "COMPLETED",
       "last_update": "2026-02-11",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04089215",
       "title": "CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2023-11-24",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04205838",
       "title": "Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma",
       "status": "TERMINATED",
       "last_update": "2026-02-27",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04215016",
       "title": "Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2020-01-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04231747",
       "title": "A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
       "status": "COMPLETED",
       "last_update": "2024-05-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04257578",
       "title": "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-06-25",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04271410",
       "title": "CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2023-04-18",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04316624",
       "title": "A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy",
       "status": "COMPLETED",
       "last_update": "2026-02-11",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04381741",
       "title": "CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2023-02-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04432506",
       "title": "Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma",
       "status": "COMPLETED",
       "last_update": "2025-01-28",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04464200",
       "title": "19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-27",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04486872",
       "title": "An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection",
       "status": "UNKNOWN",
       "last_update": "2020-08-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04488354",
       "title": "Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T",
       "status": "COMPLETED",
       "last_update": "2026-04-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04726787",
       "title": "RadiothErapy priMIng for CAR-T",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2024-12-09",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04745559",
       "title": "Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-01-29",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04787263",
       "title": "CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-12-02",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04812691",
       "title": "CD19-targeted CAR T Cells \uff08JWCAR029\uff09 for Primary Refractory Diffuse Large B Cell Lymphoma",
       "status": "COMPLETED",
       "last_update": "2023-11-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04844086",
       "title": "RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies",
       "status": "TERMINATED",
       "last_update": "2022-05-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04855253",
       "title": "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL",
       "status": "SUSPENDED",
       "last_update": "2026-01-15",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04890236",
       "title": "Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study",
       "status": "COMPLETED",
       "last_update": "2025-01-20",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05020392",
       "title": "Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2023-07-25",
       "phase": "PHASE3",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05075603",
       "title": "Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy",
       "status": "COMPLETED",
       "last_update": "2026-08-10",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05108805",
       "title": "Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting",
       "status": "COMPLETED",
       "last_update": "2025-03-27",
       "phase": "PHASE4",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05359211",
       "title": "NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-03-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05404048",
       "title": "PD-L1 PET-imaging During CAR T-cell Therapy",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-12-03",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05487651",
       "title": "Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies",
       "status": "UNKNOWN",
       "last_update": "2023-05-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05664217",
       "title": "NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma",
       "status": "TERMINATED",
       "last_update": "2025-02-13",
       "phase": "PHASE2/PHASE3",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05665062",
       "title": "Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-10",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05673447",
       "title": "The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2023-08-28",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05675982",
       "title": "Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-01-02",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05715606",
       "title": "Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research",
       "status": "UNKNOWN",
       "last_update": "2023-07-05",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06003179",
       "title": "Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah",
       "status": "WITHDRAWN",
       "last_update": "2024-11-12",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06149169",
       "title": "CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2024-08-21",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06343376",
       "title": "Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies",
       "status": "TERMINATED",
       "last_update": "2025-08-03",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06552572",
       "title": "Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-05-21",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06827782",
       "title": "Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma",
       "status": "ENROLLING_BY_INVITATION",
       "last_update": "2025-08-15",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07098364",
       "title": "ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma",
       "status": "SUSPENDED",
       "last_update": "2026-09-11",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07168291",
       "title": "Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-09-17",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07326371",
       "title": "Glofitamab Combined With CAR-T Therapy in R/R DLBCL",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-01-08",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07412405",
       "title": "This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-02-17",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07725406",
       "title": "Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-07-24",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD19",
     "axicabtagene",
     "axi-cel",
     "Yescarta",
     "lisocabtagene",
     "liso-cel",
     "Breyanzi",
     "tisagenlecleucel",
     "Kymriah",
     "tafasitamab",
     "loncastuximab"
    ]
   },
   "CD20": {
    "n": 398,
    "n_observational": 36,
    "n_active": 141,
    "n_withdrawn": 14,
    "trials": [
     {
      "nct": "NCT02393157",
      "title": "Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL",
      "status": "RECRUITING",
      "last_update": "2025-08-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03223610",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03418038",
      "title": "Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04186520",
      "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04830137",
      "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04844866",
      "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04889716",
      "title": "CAR-T Followed by Bispecific Antibodies",
      "status": "RECRUITING",
      "last_update": "2026-05-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05052528",
      "title": "Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05131022",
      "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05257018",
      "title": "R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05389423",
      "title": "Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05518383",
      "title": "B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021",
      "status": "RECRUITING",
      "last_update": "2022-08-26",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05633615",
      "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05672251",
      "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05800366",
      "title": "A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05852717",
      "title": "Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06015880",
      "title": "Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06045247",
      "title": "Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06050694",
      "title": "Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)",
      "status": "RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06091865",
      "title": "A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06209619",
      "title": "CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06238648",
      "title": "Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy",
      "status": "RECRUITING",
      "last_update": "2024-09-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06244368",
      "title": "GVM\u00b1R in Patients With Relapsed or Refractory Aggressive NHL.",
      "status": "RECRUITING",
      "last_update": "2025-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06249191",
      "title": "Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06287398",
      "title": "Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL",
      "status": "RECRUITING",
      "last_update": "2024-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06458439",
      "title": "Epcoritamab-CAR T Cells for Large B-cell Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06517004",
      "title": "An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06536049",
      "title": "Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06570447",
      "title": "Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06594939",
      "title": "Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06624085",
      "title": "A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06649812",
      "title": "Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06651853",
      "title": "Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06672705",
      "title": "Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders",
      "status": "RECRUITING",
      "last_update": "2025-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06682130",
      "title": "Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06683885",
      "title": "A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-11-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06693830",
      "title": "ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-01-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06703892",
      "title": "A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06735664",
      "title": "Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation",
      "status": "RECRUITING",
      "last_update": "2025-09-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06742502",
      "title": "Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL",
      "status": "RECRUITING",
      "last_update": "2025-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06758037",
      "title": "Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2025-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06765317",
      "title": "A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06784726",
      "title": "Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06806033",
      "title": "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06828991",
      "title": "A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP",
      "status": "RECRUITING",
      "last_update": "2025-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06829771",
      "title": "Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06854159",
      "title": "Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06854445",
      "title": "Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06867536",
      "title": "Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden",
      "status": "RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06905509",
      "title": "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06929624",
      "title": "A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06931652",
      "title": "Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07001540",
      "title": "Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation",
      "status": "RECRUITING",
      "last_update": "2025-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07097363",
      "title": "Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07126236",
      "title": "Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07188558",
      "title": "A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07189065",
      "title": "A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07197307",
      "title": "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07255963",
      "title": "Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-12-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07284433",
      "title": "Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07288879",
      "title": "DALY II Japan/MB-CART2019.1 for DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07365306",
      "title": "Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07451652",
      "title": "Low Dose Epcoritamab Plus GemOx in R/R DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493148",
      "title": "Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07528352",
      "title": "External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07548697",
      "title": "A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07654426",
      "title": "The CARDIOPROTECT Trial",
      "status": "RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07749365",
      "title": "Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07778212",
      "title": "Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00001337",
      "title": "Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003150",
      "title": "Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-06-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003397",
      "title": "Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003595",
      "title": "Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-02-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004031",
      "title": "SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-02-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004039",
      "title": "Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2015-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004112",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005089",
      "title": "S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005601",
      "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005631",
      "title": "Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006436",
      "title": "EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection",
      "status": "COMPLETED",
      "last_update": "2026-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006669",
      "title": "Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2021-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00007852",
      "title": "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00012051",
      "title": "Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00017381",
      "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-01-09",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00022971",
      "title": "Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2019-12-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00032019",
      "title": "Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00049036",
      "title": "Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00052923",
      "title": "Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2009-02-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00052936",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00055640",
      "title": "Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2010-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00059904",
      "title": "Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-07-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00062114",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00062296",
      "title": "Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00064116",
      "title": "Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-04-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00069966",
      "title": "Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse",
      "status": "UNKNOWN",
      "last_update": "2009-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00070018",
      "title": "S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-01-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00072514",
      "title": "Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073918",
      "title": "Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073931",
      "title": "Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073957",
      "title": "Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080886",
      "title": "Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080925",
      "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2012-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00088881",
      "title": "Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2017-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101010",
      "title": "Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00107380",
      "title": "S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00118209",
      "title": "Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-11-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00119392",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00135499",
      "title": "R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-08-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00144807",
      "title": "ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00151320",
      "title": "Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL",
      "status": "COMPLETED",
      "last_update": "2018-06-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00169169",
      "title": "Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2005-09-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00169195",
      "title": "Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00176475",
      "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",
      "status": "TERMINATED",
      "last_update": "2013-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00216164",
      "title": "Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2011-05-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00225212",
      "title": "Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244946",
      "title": "Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244985",
      "title": "Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00268853",
      "title": "A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin",
      "status": "COMPLETED",
      "last_update": "2024-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00274924",
      "title": "Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00278408",
      "title": "Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-08-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00278421",
      "title": "Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-03-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00290667",
      "title": "Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00355199",
      "title": "Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.",
      "status": "COMPLETED",
      "last_update": "2017-08-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00398372",
      "title": "Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment",
      "status": "COMPLETED",
      "last_update": "2011-06-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00400478",
      "title": "A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13",
      "status": "COMPLETED",
      "last_update": "2016-05-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00436280",
      "title": "Chemotherapy for Participants With Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00438880",
      "title": "Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00451178",
      "title": "A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only",
      "status": "COMPLETED",
      "last_update": "2020-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00486759",
      "title": "A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2017-07-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00490009",
      "title": "Phase 2 Study of Bexxar in Relapsed/Refractory DLCL",
      "status": "COMPLETED",
      "last_update": "2017-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00498043",
      "title": "A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00521261",
      "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2014-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00536978",
      "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2020-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00553943",
      "title": "Phase II Study to Evaluate the Combination of Rituximab and DepoCyte\u00ae in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis",
      "status": "COMPLETED",
      "last_update": "2018-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00556127",
      "title": "Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2007-11-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00561756",
      "title": "Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00562978",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2021-06-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00590941",
      "title": "Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-05-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00596804",
      "title": "Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00599170",
      "title": "Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00617929",
      "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00655837",
      "title": "Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL",
      "status": "COMPLETED",
      "last_update": "2014-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00691652",
      "title": "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-11-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00695409",
      "title": "Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00719472",
      "title": "A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)",
      "status": "COMPLETED",
      "last_update": "2017-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720135",
      "title": "Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00736450",
      "title": "Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-10-24",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00765245",
      "title": "Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-04-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00785330",
      "title": "Allo-hNHL (FluBuCy)",
      "status": "COMPLETED",
      "last_update": "2020-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00790036",
      "title": "Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy",
      "status": "COMPLETED",
      "last_update": "2017-07-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00818961",
      "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2013-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00834951",
      "title": "Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2009-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00851552",
      "title": "Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment",
      "status": "TERMINATED",
      "last_update": "2014-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00867087",
      "title": "Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00867529",
      "title": "Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-01-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00880815",
      "title": "Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2019-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00972478",
      "title": "Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00980304",
      "title": "R Retreatment in 1st Relapsed DLBCL",
      "status": "UNKNOWN",
      "last_update": "2009-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00987493",
      "title": "Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00992446",
      "title": "Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01009970",
      "title": "Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet\u00ae), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2011-10-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01044745",
      "title": "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2023-09-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01054781",
      "title": "Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2012-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01087424",
      "title": "Mini-CHOP and Rituximab in Patients Aged Over 80 Years",
      "status": "COMPLETED",
      "last_update": "2019-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01101581",
      "title": "Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL",
      "status": "WITHDRAWN",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01144403",
      "title": "A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.",
      "status": "TERMINATED",
      "last_update": "2016-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01193842",
      "title": "Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2023-11-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01195714",
      "title": "Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years",
      "status": "COMPLETED",
      "last_update": "2018-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01197560",
      "title": "Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2019-11-25",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01210287",
      "title": "Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP",
      "status": "UNKNOWN",
      "last_update": "2014-01-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01238692",
      "title": "A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01277172",
      "title": "TREatment of degeNerative and Neoplastic Diseases With Rituximab",
      "status": "UNKNOWN",
      "last_update": "2011-01-14",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01278602",
      "title": "R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2013-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01279902",
      "title": "Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL",
      "status": "UNKNOWN",
      "last_update": "2016-07-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01285765",
      "title": "Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients",
      "status": "COMPLETED",
      "last_update": "2020-07-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01287741",
      "title": "A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)",
      "status": "TERMINATED",
      "last_update": "2019-04-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01326702",
      "title": "Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-12-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01397591",
      "title": "Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2014-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01414855",
      "title": "A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)",
      "status": "COMPLETED",
      "last_update": "2018-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01419795",
      "title": "Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01434472",
      "title": "High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2021-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01448096",
      "title": "Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01459887",
      "title": "Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2011-10-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01510184",
      "title": "Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy",
      "status": "TERMINATED",
      "last_update": "2021-12-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01539174",
      "title": "Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01555541",
      "title": "Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01562990",
      "title": "Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse",
      "status": "COMPLETED",
      "last_update": "2016-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01569750",
      "title": "A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01622439",
      "title": "Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-03-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01649856",
      "title": "A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01653067",
      "title": "STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01659099",
      "title": "GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-03-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01680991",
      "title": "A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease",
      "status": "COMPLETED",
      "last_update": "2016-04-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01691898",
      "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)",
      "status": "COMPLETED",
      "last_update": "2020-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01724021",
      "title": "A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a",
      "status": "COMPLETED",
      "last_update": "2018-01-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01735604",
      "title": "Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy",
      "status": "UNKNOWN",
      "last_update": "2015-09-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01804127",
      "title": "Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL",
      "status": "UNKNOWN",
      "last_update": "2013-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01805557",
      "title": "Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.",
      "status": "COMPLETED",
      "last_update": "2022-06-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01842672",
      "title": "Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-10-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01855750",
      "title": "A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-02-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01856192",
      "title": "Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01914718",
      "title": "Dose-adjusted EPOCH-R in MYC Positive DLBCL",
      "status": "TERMINATED",
      "last_update": "2014-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01925612",
      "title": "Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2018-06-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01939327",
      "title": "Safety and Efficacy of Revlimid\u00ae (Lenalidomide) With Mabthera\u00ae (Rituximab) in Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01987505",
      "title": "MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-12-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01990144",
      "title": "Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL",
      "status": "UNKNOWN",
      "last_update": "2013-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02060656",
      "title": "Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)",
      "status": "UNKNOWN",
      "last_update": "2019-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02077166",
      "title": "Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02141451",
      "title": "ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL",
      "status": "COMPLETED",
      "last_update": "2020-02-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02168907",
      "title": "CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02205333",
      "title": "A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies",
      "status": "TERMINATED",
      "last_update": "2017-06-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02219737",
      "title": "Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02220842",
      "title": "A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-01-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02257567",
      "title": "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-11-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02285062",
      "title": "Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-06-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02290951",
      "title": "Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02329080",
      "title": "New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement",
      "status": "COMPLETED",
      "last_update": "2025-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02348216",
      "title": "Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02361346",
      "title": "Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL",
      "status": "TERMINATED",
      "last_update": "2022-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02366663",
      "title": "BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin\u00ae)/BEAM With ASCT for Relapsed DLBCL",
      "status": "TERMINATED",
      "last_update": "2018-03-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02417285",
      "title": "A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.",
      "status": "COMPLETED",
      "last_update": "2023-10-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02420210",
      "title": "Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02446457",
      "title": "Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02483000",
      "title": "Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2020-11-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02495454",
      "title": "GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2020-11-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02499003",
      "title": "GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02529852",
      "title": "A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02531308",
      "title": "Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2022-09-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02532192",
      "title": "A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02541565",
      "title": "Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-10-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02589145",
      "title": "Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype",
      "status": "TERMINATED",
      "last_update": "2019-12-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02594163",
      "title": "Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-10-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02596971",
      "title": "A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2021-05-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02600897",
      "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-12-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02611323",
      "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-10-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02624986",
      "title": "A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants",
      "status": "TERMINATED",
      "last_update": "2020-05-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02628405",
      "title": "R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2024-07-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02636322",
      "title": "Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib",
      "status": "COMPLETED",
      "last_update": "2024-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02653989",
      "title": "Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "WITHDRAWN",
      "last_update": "2016-11-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02670317",
      "title": "Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.",
      "status": "TERMINATED",
      "last_update": "2017-03-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02700022",
      "title": "A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas",
      "status": "TERMINATED",
      "last_update": "2017-11-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02729896",
      "title": "A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2020-12-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02734771",
      "title": "A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02737085",
      "title": "the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)",
      "status": "UNKNOWN",
      "last_update": "2016-09-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02747732",
      "title": "Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL",
      "status": "UNKNOWN",
      "last_update": "2019-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02752815",
      "title": "Reduced Chemotherapy in Low Risk DLBCL",
      "status": "UNKNOWN",
      "last_update": "2022-12-05",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02753647",
      "title": "Chidamide Plus R-CHOP in Elderly DLBCL",
      "status": "UNKNOWN",
      "last_update": "2017-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02758925",
      "title": "CyBeR Association in Relapsed/Refractory DLBCL",
      "status": "UNKNOWN",
      "last_update": "2016-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02772822",
      "title": "A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients",
      "status": "UNKNOWN",
      "last_update": "2016-05-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02842931",
      "title": "R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis",
      "status": "UNKNOWN",
      "last_update": "2016-07-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02846584",
      "title": "a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2016-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02867566",
      "title": "A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2020-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890602",
      "title": "Erythropoietin for Management of Anemia Caused by Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2020-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02924402",
      "title": "Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02951156",
      "title": "Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",
      "status": "TERMINATED",
      "last_update": "2020-12-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02961816",
      "title": "Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2017-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983097",
      "title": "Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP",
      "status": "TERMINATED",
      "last_update": "2018-01-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02987400",
      "title": "Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL",
      "status": "COMPLETED",
      "last_update": "2022-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02992522",
      "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03019640",
      "title": "Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03019666",
      "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
      "status": "COMPLETED",
      "last_update": "2022-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03023878",
      "title": "Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03036904",
      "title": "Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2022-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03097770",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20",
      "status": "COMPLETED",
      "last_update": "2020-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03129828",
      "title": "Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI \u2265 2",
      "status": "COMPLETED",
      "last_update": "2024-12-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03135262",
      "title": "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2021-12-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03136497",
      "title": "A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03151044",
      "title": "R\u00b1CEOP90 Versus R\u00b1CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL",
      "status": "UNKNOWN",
      "last_update": "2017-05-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03200015",
      "title": "Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03201471",
      "title": "Chidamide With R-CHOP Regimen for DLBCL Patients",
      "status": "UNKNOWN",
      "last_update": "2018-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03220022",
      "title": "Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03244176",
      "title": "Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study",
      "status": "UNKNOWN",
      "last_update": "2024-07-30",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03259503",
      "title": "Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03259529",
      "title": "Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL",
      "status": "COMPLETED",
      "last_update": "2021-06-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03276468",
      "title": "Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas",
      "status": "COMPLETED",
      "last_update": "2023-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03283202",
      "title": "Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors",
      "status": "COMPLETED",
      "last_update": "2021-04-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03321643",
      "title": "Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03399747",
      "title": "Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2018-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03401853",
      "title": "Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03458260",
      "title": "Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03467373",
      "title": "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL",
      "status": "COMPLETED",
      "last_update": "2025-01-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03485118",
      "title": "RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03513601",
      "title": "Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2018-05-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03579927",
      "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2020-01-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03650933",
      "title": "A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients",
      "status": "UNKNOWN",
      "last_update": "2024-02-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03677154",
      "title": "Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03704714",
      "title": "Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma",
      "status": "SUSPENDED",
      "last_update": "2022-08-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03736616",
      "title": "Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL",
      "status": "UNKNOWN",
      "last_update": "2022-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03742258",
      "title": "Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03749018",
      "title": "Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03777085",
      "title": "Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "UNKNOWN",
      "last_update": "2019-05-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03795571",
      "title": "Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL",
      "status": "UNKNOWN",
      "last_update": "2019-02-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03864419",
      "title": "Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda",
      "status": "TERMINATED",
      "last_update": "2024-01-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03888105",
      "title": "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03943901",
      "title": "Split-Dose R-CHOP for Older Adults With DLBCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03984448",
      "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03995147",
      "title": "Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04007029",
      "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04022005",
      "title": "Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL",
      "status": "COMPLETED",
      "last_update": "2023-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04049825",
      "title": "A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL",
      "status": "COMPLETED",
      "last_update": "2026-04-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04164368",
      "title": "Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2024-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04176913",
      "title": "Study of LUCAR-20S in Patients With R/R NHL",
      "status": "TERMINATED",
      "last_update": "2022-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04214444",
      "title": "Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab",
      "status": "COMPLETED",
      "last_update": "2026-02-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04215016",
      "title": "Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2020-01-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04231877",
      "title": "Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04279938",
      "title": "A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL",
      "status": "WITHDRAWN",
      "last_update": "2020-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04285268",
      "title": "Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2026-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04313608",
      "title": "A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-03-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04316624",
      "title": "A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy",
      "status": "COMPLETED",
      "last_update": "2026-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04323956",
      "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04358458",
      "title": "First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2024-10-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04361279",
      "title": "A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL",
      "status": "COMPLETED",
      "last_update": "2023-12-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04404283",
      "title": "Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04408638",
      "title": "A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04425824",
      "title": "Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2020-06-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04436107",
      "title": "Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04442022",
      "title": "A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04479267",
      "title": "Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04486872",
      "title": "An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection",
      "status": "UNKNOWN",
      "last_update": "2020-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04517435",
      "title": "ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-02-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04542824",
      "title": "Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04546620",
      "title": "Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04609046",
      "title": "Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04628494",
      "title": "A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04657302",
      "title": "A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-01-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04659434",
      "title": "Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL",
      "status": "UNKNOWN",
      "last_update": "2020-12-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04663347",
      "title": "Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665765",
      "title": "Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04703686",
      "title": "Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy",
      "status": "COMPLETED",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04735471",
      "title": "A Phase 1 Study of ADI-001 in B Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04739813",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04833114",
      "title": "Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2026-06-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04842487",
      "title": "R2-CHOP in Untreated DEL-DLBCL\uff1aAn Open-lable\uff0cMulticenter\uff0cPhase II Study",
      "status": "UNKNOWN",
      "last_update": "2021-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04850495",
      "title": "Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04914741",
      "title": "A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)",
      "status": "UNKNOWN",
      "last_update": "2024-08-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04974996",
      "title": "A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)",
      "status": "WITHDRAWN",
      "last_update": "2022-03-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04978584",
      "title": "Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04980222",
      "title": "A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05040906",
      "title": "A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients",
      "status": "UNKNOWN",
      "last_update": "2021-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05115409",
      "title": "Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)",
      "status": "UNKNOWN",
      "last_update": "2022-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05169489",
      "title": "A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)",
      "status": "TERMINATED",
      "last_update": "2025-10-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05179733",
      "title": "The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years",
      "status": "UNKNOWN",
      "last_update": "2023-05-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05189197",
      "title": "A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression",
      "status": "UNKNOWN",
      "last_update": "2024-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05206357",
      "title": "Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05211336",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05221645",
      "title": "Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05280626",
      "title": "First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-03-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05335018",
      "title": "GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05364424",
      "title": "A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-12-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05412290",
      "title": "Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05421663",
      "title": "A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05428670",
      "title": "The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.",
      "status": "UNKNOWN",
      "last_update": "2022-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05451810",
      "title": "A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05575973",
      "title": "Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2022-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05578976",
      "title": "A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05660967",
      "title": "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05777369",
      "title": "R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05798156",
      "title": "Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05823701",
      "title": "Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients",
      "status": "UNKNOWN",
      "last_update": "2023-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05896163",
      "title": "A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.",
      "status": "TERMINATED",
      "last_update": "2026-05-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05940051",
      "title": "Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06062641",
      "title": "Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06247540",
      "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2024-02-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06508658",
      "title": "A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06516978",
      "title": "A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06530511",
      "title": "Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL",
      "status": "UNKNOWN",
      "last_update": "2025-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06552572",
      "title": "Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06665217",
      "title": "G-Pola-ZLP in Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06890585",
      "title": "Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06925555",
      "title": "Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07012980",
      "title": "Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07024147",
      "title": "JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07030699",
      "title": "A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07034508",
      "title": "A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07035379",
      "title": "A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone\uff08T-CHP\uff09 in Previously Untreated Patients With CD20-positive DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07159906",
      "title": "Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07220187",
      "title": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07226752",
      "title": "A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231250",
      "title": "Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07269639",
      "title": "Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07326371",
      "title": "Glofitamab Combined With CAR-T Therapy in R/R DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07387848",
      "title": "Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07480850",
      "title": "Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07502872",
      "title": "TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07588698",
      "title": "Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07599423",
      "title": "A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07634289",
      "title": "Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07649304",
      "title": "AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The \"Glofit-RCHOP Study\")",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07702851",
      "title": "A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07714421",
      "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07744737",
      "title": "Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07744750",
      "title": "Pirtobrutinib+Sonrotoclax\uff08PS) Regimen in the Treatment of B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07748364",
      "title": "Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07764601",
      "title": "R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07774234",
      "title": "Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07814001",
      "title": "Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 32,
     "n_observational": 2,
     "n_active": 18,
     "n_withdrawn": 2,
     "trials": [
      {
       "nct": "NCT04186520",
       "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-02-23",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04844866",
       "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients",
       "status": "RECRUITING",
       "last_update": "2026-06-10",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04889716",
       "title": "CAR-T Followed by Bispecific Antibodies",
       "status": "RECRUITING",
       "last_update": "2026-05-26",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05052528",
       "title": "Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-07-17",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05633615",
       "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-02-02",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06209619",
       "title": "CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-02-27",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06238648",
       "title": "Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy",
       "status": "RECRUITING",
       "last_update": "2024-09-26",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06458439",
       "title": "Epcoritamab-CAR T Cells for Large B-cell Lymphomas",
       "status": "RECRUITING",
       "last_update": "2026-05-27",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06703892",
       "title": "A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-06-12",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06784726",
       "title": "Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T",
       "status": "RECRUITING",
       "last_update": "2026-08-28",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06854159",
       "title": "Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy",
       "status": "RECRUITING",
       "last_update": "2026-07-08",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07188558",
       "title": "A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",
       "status": "RECRUITING",
       "last_update": "2026-08-04",
       "phase": "PHASE3",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07284433",
       "title": "Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-08-28",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07288879",
       "title": "DALY II Japan/MB-CART2019.1 for DLBCL",
       "status": "RECRUITING",
       "last_update": "2026-01-08",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00176475",
       "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",
       "status": "TERMINATED",
       "last_update": "2013-09-17",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00521261",
       "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
       "status": "WITHDRAWN",
       "last_update": "2014-03-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01735604",
       "title": "Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy",
       "status": "UNKNOWN",
       "last_update": "2015-09-29",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02737085",
       "title": "the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)",
       "status": "UNKNOWN",
       "last_update": "2016-09-07",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02846584",
       "title": "a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies",
       "status": "UNKNOWN",
       "last_update": "2016-09-07",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03019640",
       "title": "Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma",
       "status": "COMPLETED",
       "last_update": "2023-02-16",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03019666",
       "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
       "status": "COMPLETED",
       "last_update": "2022-11-04",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03097770",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20",
       "status": "COMPLETED",
       "last_update": "2020-09-02",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03579927",
       "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",
       "status": "WITHDRAWN",
       "last_update": "2020-01-29",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04007029",
       "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04215016",
       "title": "Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2020-01-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04316624",
       "title": "A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy",
       "status": "COMPLETED",
       "last_update": "2026-02-11",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04486872",
       "title": "An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection",
       "status": "UNKNOWN",
       "last_update": "2020-08-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04703686",
       "title": "Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy",
       "status": "COMPLETED",
       "last_update": "2026-03-16",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05364424",
       "title": "A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma",
       "status": "COMPLETED",
       "last_update": "2025-12-01",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06552572",
       "title": "Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-05-21",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07326371",
       "title": "Glofitamab Combined With CAR-T Therapy in R/R DLBCL",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-01-08",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07814001",
       "title": "Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-09-10",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD20",
     "MS4A1",
     "rituximab",
     "obinutuzumab",
     "glofitamab",
     "epcoritamab",
     "mosunetuzumab",
     "odronextamab"
    ]
   },
   "CD79b": {
    "n": 72,
    "n_observational": 6,
    "n_active": 49,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT04332822",
      "title": "A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04491370",
      "title": "Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04844866",
      "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05633615",
      "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05800366",
      "title": "A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06015880",
      "title": "Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06026319",
      "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06050694",
      "title": "Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)",
      "status": "RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06176729",
      "title": "Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients",
      "status": "RECRUITING",
      "last_update": "2023-12-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06522555",
      "title": "The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-08-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06554600",
      "title": "A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06594939",
      "title": "Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06664411",
      "title": "Pola-ZR2P in Previously Untreated DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06765317",
      "title": "A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06803693",
      "title": "Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06846463",
      "title": "Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+",
      "status": "RECRUITING",
      "last_update": "2026-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06890884",
      "title": "A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07001540",
      "title": "Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation",
      "status": "RECRUITING",
      "last_update": "2025-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07072208",
      "title": "Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-07-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07371923",
      "title": "Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07397832",
      "title": "CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07499271",
      "title": "Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation",
      "status": "RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07608978",
      "title": "Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes",
      "status": "RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07654426",
      "title": "The CARDIOPROTECT Trial",
      "status": "RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07680933",
      "title": "Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07778212",
      "title": "Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01691898",
      "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)",
      "status": "COMPLETED",
      "last_update": "2020-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02257567",
      "title": "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-11-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02600897",
      "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-12-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02611323",
      "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-10-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02729896",
      "title": "A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2020-12-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03274492",
      "title": "A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-05-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03467373",
      "title": "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL",
      "status": "COMPLETED",
      "last_update": "2025-01-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03677154",
      "title": "Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04182204",
      "title": "A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-12-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04231877",
      "title": "Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04236141",
      "title": "A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).",
      "status": "TERMINATED",
      "last_update": "2023-03-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04323956",
      "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04479267",
      "title": "Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04535102",
      "title": "POLA+BR for Relapsed or Refractory DLBCL",
      "status": "WITHDRAWN",
      "last_update": "2022-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04607772",
      "title": "Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "WITHDRAWN",
      "last_update": "2025-10-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665765",
      "title": "Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04668365",
      "title": "Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma",
      "status": "SUSPENDED",
      "last_update": "2025-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04739813",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04790903",
      "title": "A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2024-07-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04833114",
      "title": "Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2026-06-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04914741",
      "title": "A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)",
      "status": "UNKNOWN",
      "last_update": "2024-08-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05068440",
      "title": "Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib",
      "status": "COMPLETED",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05319028",
      "title": "Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2023-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05455697",
      "title": "Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05498220",
      "title": "Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05798156",
      "title": "Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05940051",
      "title": "Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05940064",
      "title": "Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05966233",
      "title": "R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2024-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06441097",
      "title": "Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06516978",
      "title": "A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06530511",
      "title": "Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL",
      "status": "UNKNOWN",
      "last_update": "2025-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06665217",
      "title": "G-Pola-ZLP in Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07012980",
      "title": "Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07034508",
      "title": "A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07122609",
      "title": "Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231250",
      "title": "Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07398638",
      "title": "Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07415980",
      "title": "Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07502872",
      "title": "TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07677813",
      "title": "Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07702851",
      "title": "A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07714421",
      "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07744724",
      "title": "Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07812493",
      "title": "Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 3,
     "n_observational": 0,
     "n_active": 3,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04844866",
       "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients",
       "status": "RECRUITING",
       "last_update": "2026-06-10",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05633615",
       "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-02-02",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06026319",
       "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-03-16",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD79b",
     "polatuzumab",
     "Polivy"
    ]
   },
   "CD30": {
    "n": 23,
    "n_observational": 0,
    "n_active": 8,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT03356054",
      "title": "Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse",
      "status": "RECRUITING",
      "last_update": "2020-12-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05544968",
      "title": "Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-04-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06176690",
      "title": "Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00059995",
      "title": "MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-05-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00365274",
      "title": "SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2014-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01421667",
      "title": "A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-11-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01671813",
      "title": "Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly",
      "status": "WITHDRAWN",
      "last_update": "2013-07-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01805037",
      "title": "Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas",
      "status": "TERMINATED",
      "last_update": "2021-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01925612",
      "title": "Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2018-06-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01990534",
      "title": "A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-04-09",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01994850",
      "title": "Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2021-01-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02086604",
      "title": "Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-02-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02594163",
      "title": "Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-10-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02623920",
      "title": "Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2017-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02734771",
      "title": "A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03049449",
      "title": "T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04254107",
      "title": "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer",
      "status": "TERMINATED",
      "last_update": "2025-02-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04404283",
      "title": "Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04526834",
      "title": "Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05208853",
      "title": "An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2022-01-26",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06186986",
      "title": "CD30 Imaging in Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2024-01-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06925555",
      "title": "Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07729397",
      "title": "Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 3,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT03049449",
       "title": "T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas",
       "status": "COMPLETED",
       "last_update": "2023-01-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04526834",
       "title": "Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2023-04-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05208853",
       "title": "An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2022-01-26",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD30",
     "brentuximab"
    ]
   },
   "CD22": {
    "n": 21,
    "n_observational": 1,
    "n_active": 6,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT06081478",
      "title": "CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2023-10-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06208735",
      "title": "CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-04-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06213636",
      "title": "Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).",
      "status": "RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004086",
      "title": "Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer",
      "status": "UNKNOWN",
      "last_update": "2009-06-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004107",
      "title": "Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia",
      "status": "COMPLETED",
      "last_update": "2011-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00007956",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00024115",
      "title": "BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2015-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00867087",
      "title": "Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00889408",
      "title": "DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01101581",
      "title": "Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL",
      "status": "WITHDRAWN",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01232556",
      "title": "A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy",
      "status": "TERMINATED",
      "last_update": "2019-01-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01562990",
      "title": "Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse",
      "status": "COMPLETED",
      "last_update": "2016-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02721407",
      "title": "Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients",
      "status": "UNKNOWN",
      "last_update": "2017-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03185494",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22",
      "status": "UNKNOWN",
      "last_update": "2019-04-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03287817",
      "title": "Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-07-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03682796",
      "title": "Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03999697",
      "title": "A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2019-06-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05972720",
      "title": "A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06285422",
      "title": "Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07168291",
      "title": "Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07735533",
      "title": "A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 7,
     "n_observational": 1,
     "n_active": 3,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT06081478",
       "title": "CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2023-10-13",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06213636",
       "title": "Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).",
       "status": "RECRUITING",
       "last_update": "2025-08-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02721407",
       "title": "Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients",
       "status": "UNKNOWN",
       "last_update": "2017-03-10",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03185494",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22",
       "status": "UNKNOWN",
       "last_update": "2019-04-17",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03287817",
       "title": "Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma",
       "status": "TERMINATED",
       "last_update": "2025-07-14",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03999697",
       "title": "A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies",
       "status": "UNKNOWN",
       "last_update": "2019-06-27",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07168291",
       "title": "Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-09-17",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD22"
    ]
   },
   "BCL-2": {
    "n": 63,
    "n_observational": 7,
    "n_active": 26,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT03223610",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05131022",
      "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06649812",
      "title": "Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06701357",
      "title": "CR-CHOP+X in Previously Untreated DEL",
      "status": "RECRUITING",
      "last_update": "2024-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06736613",
      "title": "A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06764017",
      "title": "CHiR Therapy for Elderly DLBCL Intolerant to Chemo",
      "status": "RECRUITING",
      "last_update": "2025-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06806033",
      "title": "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859008",
      "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493148",
      "title": "Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07609862",
      "title": "A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054639",
      "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054665",
      "title": "PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00060112",
      "title": "Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma",
      "status": "TERMINATED",
      "last_update": "2013-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080847",
      "title": "S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2013-01-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00086944",
      "title": "Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00169130",
      "title": "ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2007-07-13",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00736450",
      "title": "Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-10-24",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00933985",
      "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia",
      "status": "TERMINATED",
      "last_update": "2014-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01742988",
      "title": "Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02226965",
      "title": "PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)",
      "status": "COMPLETED",
      "last_update": "2023-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02611323",
      "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-10-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02987400",
      "title": "Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL",
      "status": "COMPLETED",
      "last_update": "2022-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02992522",
      "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03036904",
      "title": "Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2022-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03064867",
      "title": "Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2022-11-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03082209",
      "title": "A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-12-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03132584",
      "title": "Cyclophosphamide and Alemtuzumab In Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-01-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03135262",
      "title": "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2021-12-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03136497",
      "title": "A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03255096",
      "title": "A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6",
      "status": "COMPLETED",
      "last_update": "2022-01-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03276468",
      "title": "Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas",
      "status": "COMPLETED",
      "last_update": "2023-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03357627",
      "title": "A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-02-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03530683",
      "title": "A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma",
      "status": "TERMINATED",
      "last_update": "2024-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03547115",
      "title": "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML",
      "status": "TERMINATED",
      "last_update": "2026-03-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03583424",
      "title": "Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03797261",
      "title": "A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies",
      "status": "TERMINATED",
      "last_update": "2021-12-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03886649",
      "title": "Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.",
      "status": "TERMINATED",
      "last_update": "2022-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03955783",
      "title": "Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-10-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03984448",
      "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04231448",
      "title": "Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL",
      "status": "COMPLETED",
      "last_update": "2026-04-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04285268",
      "title": "Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2026-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04572763",
      "title": "Copanlisib Plus Venetoclax in R/R DLBCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04607772",
      "title": "Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "WITHDRAWN",
      "last_update": "2025-10-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04739813",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04790903",
      "title": "A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2024-07-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04799275",
      "title": "Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04842487",
      "title": "R2-CHOP in Untreated DEL-DLBCL\uff1aAn Open-lable\uff0cMulticenter\uff0cPhase II Study",
      "status": "UNKNOWN",
      "last_update": "2021-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05211336",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05583149",
      "title": "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05618366",
      "title": "Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-04-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665530",
      "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05753501",
      "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05828589",
      "title": "A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2026-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05863845",
      "title": "Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL",
      "status": "UNKNOWN",
      "last_update": "2023-05-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06247540",
      "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2024-02-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06516978",
      "title": "A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07159906",
      "title": "Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07415980",
      "title": "Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07538180",
      "title": "Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07774234",
      "title": "Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "BCL-2",
     "venetoclax"
    ]
   }
  },
  "by_drug": {
   "ACALABRUTINIB": {
    "n": 20,
    "n_observational": 0,
    "n_active": 14,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04002947",
      "title": "Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04502394",
      "title": "Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL",
      "status": "RECRUITING",
      "last_update": "2022-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05256641",
      "title": "Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05820841",
      "title": "Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05952024",
      "title": "Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02112526",
      "title": "Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03527147",
      "title": "Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)",
      "status": "COMPLETED",
      "last_update": "2022-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03571308",
      "title": "A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-09-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03736616",
      "title": "Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL",
      "status": "UNKNOWN",
      "last_update": "2022-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03899337",
      "title": "A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04189952",
      "title": "Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04257578",
      "title": "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04529772",
      "title": "A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04546620",
      "title": "Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04604067",
      "title": "Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04978584",
      "title": "Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05583149",
      "title": "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06441097",
      "title": "Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "APG-2575": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07159906",
      "title": "Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AXICABTAGENE CILOLEUCEL": {
    "n": 20,
    "n_observational": 3,
    "n_active": 11,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05077527",
      "title": "Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05633615",
      "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05757219",
      "title": "Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06550141",
      "title": "Emapalumab Prevention of CAR-T Cell Associated Toxicities",
      "status": "RECRUITING",
      "last_update": "2025-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06902012",
      "title": "Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-03-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07042438",
      "title": "Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells",
      "status": "RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07188558",
      "title": "A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07254754",
      "title": "Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02348216",
      "title": "Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02926833",
      "title": "Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2024-03-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03391466",
      "title": "Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-12-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03954106",
      "title": "A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity",
      "status": "TERMINATED",
      "last_update": "2021-12-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04205838",
      "title": "Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04257578",
      "title": "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04432506",
      "title": "Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04855253",
      "title": "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL",
      "status": "SUSPENDED",
      "last_update": "2026-01-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05075603",
      "title": "Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy",
      "status": "COMPLETED",
      "last_update": "2026-08-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05108805",
      "title": "Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting",
      "status": "COMPLETED",
      "last_update": "2025-03-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07326371",
      "title": "Glofitamab Combined With CAR-T Therapy in R/R DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07725406",
      "title": "Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BLINATUMOMAB": {
    "n": 6,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01741792",
      "title": "Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2017-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02568553",
      "title": "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-11-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03023878",
      "title": "Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03072771",
      "title": "Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03298412",
      "title": "Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)",
      "status": "TERMINATED",
      "last_update": "2020-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03340766",
      "title": "Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2024-10-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "COLTUXIMAB RAVTANSINE": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01470456",
      "title": "Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01472887",
      "title": "SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients",
      "status": "COMPLETED",
      "last_update": "2018-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DENINTUZUMAB MAFODOTIN": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01786135",
      "title": "A Safety Study of SGN-CD19A for B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02592876",
      "title": "Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02855359",
      "title": "Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "EPCORITAMAB": {
    "n": 30,
    "n_observational": 3,
    "n_active": 27,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05852717",
      "title": "Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06045247",
      "title": "Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06238648",
      "title": "Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy",
      "status": "RECRUITING",
      "last_update": "2024-09-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06287398",
      "title": "Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL",
      "status": "RECRUITING",
      "last_update": "2024-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06458439",
      "title": "Epcoritamab-CAR T Cells for Large B-cell Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06536049",
      "title": "Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06672705",
      "title": "Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders",
      "status": "RECRUITING",
      "last_update": "2025-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06905509",
      "title": "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06931652",
      "title": "Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07097363",
      "title": "Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07126236",
      "title": "Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07197307",
      "title": "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07365306",
      "title": "Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07451652",
      "title": "Low Dose Epcoritamab Plus GemOx in R/R DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07528352",
      "title": "External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04358458",
      "title": "First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2024-10-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04542824",
      "title": "Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04628494",
      "title": "A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04663347",
      "title": "Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05206357",
      "title": "Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05451810",
      "title": "A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05578976",
      "title": "A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05660967",
      "title": "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06508658",
      "title": "A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07030699",
      "title": "A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07226752",
      "title": "A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07588698",
      "title": "Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07714421",
      "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07814001",
      "title": "Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FENEBRUTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01991184",
      "title": "A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.",
      "status": "COMPLETED",
      "last_update": "2022-06-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "GLOFITAMAB": {
    "n": 38,
    "n_observational": 7,
    "n_active": 31,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04889716",
      "title": "CAR-T Followed by Bispecific Antibodies",
      "status": "RECRUITING",
      "last_update": "2026-05-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05800366",
      "title": "A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06050694",
      "title": "Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)",
      "status": "RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06570447",
      "title": "Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06624085",
      "title": "A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06651853",
      "title": "Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06682130",
      "title": "Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06765317",
      "title": "A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06806033",
      "title": "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06867536",
      "title": "Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden",
      "status": "RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07528352",
      "title": "External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07749365",
      "title": "Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03467373",
      "title": "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL",
      "status": "COMPLETED",
      "last_update": "2025-01-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04231877",
      "title": "Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04313608",
      "title": "A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-03-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04408638",
      "title": "A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04657302",
      "title": "A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-01-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04703686",
      "title": "Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy",
      "status": "COMPLETED",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04914741",
      "title": "A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)",
      "status": "UNKNOWN",
      "last_update": "2024-08-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04980222",
      "title": "A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05335018",
      "title": "GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05364424",
      "title": "A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-12-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05798156",
      "title": "Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05896163",
      "title": "A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.",
      "status": "TERMINATED",
      "last_update": "2026-05-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06552572",
      "title": "Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06665217",
      "title": "G-Pola-ZLP in Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07012980",
      "title": "Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231250",
      "title": "Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07326371",
      "title": "Glofitamab Combined With CAR-T Therapy in R/R DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07387848",
      "title": "Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07480850",
      "title": "Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07502872",
      "title": "TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07599423",
      "title": "A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07634289",
      "title": "Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07649304",
      "title": "AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The \"Glofit-RCHOP Study\")",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07702851",
      "title": "A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07748364",
      "title": "Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07774234",
      "title": "Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "GSK2816126": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02082977",
      "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma",
      "status": "TERMINATED",
      "last_update": "2020-02-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IBRUTINIB": {
    "n": 54,
    "n_observational": 0,
    "n_active": 17,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT01804686",
      "title": "A Long-term Extension Study of PCI-32765 (Ibrutinib)",
      "status": "RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03223610",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06536049",
      "title": "Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06649812",
      "title": "Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01325701",
      "title": "Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01479842",
      "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01569750",
      "title": "A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01855750",
      "title": "A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-02-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01865617",
      "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-05-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01955499",
      "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02077166",
      "title": "Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02109224",
      "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection",
      "status": "TERMINATED",
      "last_update": "2015-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02142049",
      "title": "Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02203526",
      "title": "Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02219737",
      "title": "Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02303392",
      "title": "Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-06-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02401048",
      "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas",
      "status": "COMPLETED",
      "last_update": "2019-06-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02443077",
      "title": "Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02636322",
      "title": "Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib",
      "status": "COMPLETED",
      "last_update": "2024-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02670317",
      "title": "Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.",
      "status": "TERMINATED",
      "last_update": "2017-03-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02670616",
      "title": "Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-10-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02692248",
      "title": "Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT",
      "status": "COMPLETED",
      "last_update": "2024-10-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02733042",
      "title": "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-11-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02743546",
      "title": "Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02747732",
      "title": "Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL",
      "status": "UNKNOWN",
      "last_update": "2019-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02756247",
      "title": "A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02760485",
      "title": "A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-06-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02780830",
      "title": "AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-09-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02874404",
      "title": "TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02950220",
      "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02955628",
      "title": "RICE-ibrutinib in Relapsed DLBCL",
      "status": "UNKNOWN",
      "last_update": "2017-02-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03129828",
      "title": "Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI \u2265 2",
      "status": "COMPLETED",
      "last_update": "2024-12-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03136497",
      "title": "A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03220022",
      "title": "Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03310619",
      "title": "A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-04-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03399513",
      "title": "Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03424122",
      "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03440567",
      "title": "Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03479268",
      "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03570892",
      "title": "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-06-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684694",
      "title": "Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03876028",
      "title": "Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients",
      "status": "TERMINATED",
      "last_update": "2023-01-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03939182",
      "title": "Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-04-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03949062",
      "title": "Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL",
      "status": "UNKNOWN",
      "last_update": "2021-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03960840",
      "title": "Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03964090",
      "title": "Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04025593",
      "title": "Biomarker Guided Treatment in DLBCL",
      "status": "UNKNOWN",
      "last_update": "2020-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04446962",
      "title": "LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04607772",
      "title": "Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "WITHDRAWN",
      "last_update": "2025-10-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04739813",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05211336",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IDASANUTLIN": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02624986",
      "title": "A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants",
      "status": "TERMINATED",
      "last_update": "2020-05-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03135262",
      "title": "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2021-12-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "INEBILIZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01453205",
      "title": "A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2018-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LISOCABTAGENE MARALEUCEL": {
    "n": 15,
    "n_observational": 1,
    "n_active": 7,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05633615",
      "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05873712",
      "title": "Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome",
      "status": "RECRUITING",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07188558",
      "title": "A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02631044",
      "title": "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)",
      "status": "COMPLETED",
      "last_update": "2024-06-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03483103",
      "title": "Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)",
      "status": "COMPLETED",
      "last_update": "2023-12-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03484702",
      "title": "Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-12-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03744676",
      "title": "A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)",
      "status": "COMPLETED",
      "last_update": "2025-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04855253",
      "title": "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL",
      "status": "SUSPENDED",
      "last_update": "2026-01-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05075603",
      "title": "Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy",
      "status": "COMPLETED",
      "last_update": "2026-08-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05359211",
      "title": "NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05583149",
      "title": "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05621096",
      "title": "Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05664217",
      "title": "NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-02-13",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07098364",
      "title": "ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma",
      "status": "SUSPENDED",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07725406",
      "title": "Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LONCASTUXIMAB TESIRINE": {
    "n": 17,
    "n_observational": 2,
    "n_active": 7,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT05600686",
      "title": "Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05672251",
      "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06918912",
      "title": "Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure",
      "status": "RECRUITING",
      "last_update": "2025-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06977711",
      "title": "Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Na\u00efve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07197307",
      "title": "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02669017",
      "title": "Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)",
      "status": "COMPLETED",
      "last_update": "2021-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03589469",
      "title": "Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684694",
      "title": "Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03685344",
      "title": "Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma",
      "status": "TERMINATED",
      "last_update": "2021-10-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04384484",
      "title": "Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04974996",
      "title": "A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)",
      "status": "WITHDRAWN",
      "last_update": "2022-03-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05144009",
      "title": "A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2025-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05222438",
      "title": "Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant",
      "status": "WITHDRAWN",
      "last_update": "2023-11-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05228249",
      "title": "Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2023-01-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05453396",
      "title": "Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2026-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05658562",
      "title": "A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05660395",
      "title": "A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)",
      "status": "TERMINATED",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MOSUNETUZUMAB": {
    "n": 10,
    "n_observational": 0,
    "n_active": 8,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04889716",
      "title": "CAR-T Followed by Bispecific Antibodies",
      "status": "RECRUITING",
      "last_update": "2026-05-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05633615",
      "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05672251",
      "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06015880",
      "title": "Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06249191",
      "title": "Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06594939",
      "title": "Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06828991",
      "title": "A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP",
      "status": "RECRUITING",
      "last_update": "2025-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03677154",
      "title": "Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04313608",
      "title": "A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-03-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05412290",
      "title": "Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MT-3724": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02361346",
      "title": "Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL",
      "status": "TERMINATED",
      "last_update": "2022-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03488251",
      "title": "PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2022-08-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAVITOCLAX": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT01423539",
      "title": "A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)",
      "status": "WITHDRAWN",
      "last_update": "2016-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAVTEMADLIN": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04502394",
      "title": "Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL",
      "status": "RECRUITING",
      "last_update": "2022-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02825836",
      "title": "Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Na\u00efve and R/R CLL/SLL Subjects",
      "status": "UNKNOWN",
      "last_update": "2023-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OBATOCLAX": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00538187",
      "title": "Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2015-12-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00933985",
      "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia",
      "status": "TERMINATED",
      "last_update": "2014-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OBINUTUZUMAB": {
    "n": 54,
    "n_observational": 3,
    "n_active": 25,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02393157",
      "title": "Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL",
      "status": "RECRUITING",
      "last_update": "2025-08-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03223610",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04889716",
      "title": "CAR-T Followed by Bispecific Antibodies",
      "status": "RECRUITING",
      "last_update": "2026-05-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06570447",
      "title": "Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06624085",
      "title": "A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06649812",
      "title": "Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06765317",
      "title": "A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06806033",
      "title": "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06867536",
      "title": "Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden",
      "status": "RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01287741",
      "title": "A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)",
      "status": "TERMINATED",
      "last_update": "2019-04-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01414855",
      "title": "A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)",
      "status": "COMPLETED",
      "last_update": "2018-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01659099",
      "title": "GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-03-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01680991",
      "title": "A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease",
      "status": "COMPLETED",
      "last_update": "2016-04-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01691898",
      "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)",
      "status": "COMPLETED",
      "last_update": "2020-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02220842",
      "title": "A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-01-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02257567",
      "title": "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-11-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02417285",
      "title": "A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.",
      "status": "COMPLETED",
      "last_update": "2023-10-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02420210",
      "title": "Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02495454",
      "title": "GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2020-11-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02499003",
      "title": "GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02529852",
      "title": "A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02596971",
      "title": "A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2021-05-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02600897",
      "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-12-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02611323",
      "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-10-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02624986",
      "title": "A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants",
      "status": "TERMINATED",
      "last_update": "2020-05-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02670317",
      "title": "Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.",
      "status": "TERMINATED",
      "last_update": "2017-03-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02729896",
      "title": "A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2020-12-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02987400",
      "title": "Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL",
      "status": "COMPLETED",
      "last_update": "2022-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02992522",
      "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03135262",
      "title": "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2021-12-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03276468",
      "title": "Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas",
      "status": "COMPLETED",
      "last_update": "2023-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03401853",
      "title": "Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03467373",
      "title": "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL",
      "status": "COMPLETED",
      "last_update": "2025-01-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04313608",
      "title": "A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-03-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04408638",
      "title": "A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04657302",
      "title": "A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-01-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04703686",
      "title": "Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy",
      "status": "COMPLETED",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04739813",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05211336",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05364424",
      "title": "A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-12-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05798156",
      "title": "Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05823701",
      "title": "Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients",
      "status": "UNKNOWN",
      "last_update": "2023-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05896163",
      "title": "A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.",
      "status": "TERMINATED",
      "last_update": "2026-05-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06552572",
      "title": "Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07012980",
      "title": "Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231250",
      "title": "Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07326371",
      "title": "Glofitamab Combined With CAR-T Therapy in R/R DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07480850",
      "title": "Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07502872",
      "title": "TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07599423",
      "title": "A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07634289",
      "title": "Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07702851",
      "title": "A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07744750",
      "title": "Pirtobrutinib+Sonrotoclax\uff08PS) Regimen in the Treatment of B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07774234",
      "title": "Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OBLIMERSEN": {
    "n": 6,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00054639",
      "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00060112",
      "title": "Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma",
      "status": "TERMINATED",
      "last_update": "2013-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00070083",
      "title": "Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2009-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080847",
      "title": "S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2013-01-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00086944",
      "title": "Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00736450",
      "title": "Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-10-24",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OCARATUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00003874",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ODRONEXTAMAB": {
    "n": 6,
    "n_observational": 3,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06091865",
      "title": "A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06735664",
      "title": "Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation",
      "status": "RECRUITING",
      "last_update": "2025-09-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06784726",
      "title": "Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06854159",
      "title": "Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02290951",
      "title": "Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03888105",
      "title": "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OFATUMUMAB": {
    "n": 10,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00622388",
      "title": "Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant",
      "status": "COMPLETED",
      "last_update": "2015-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00823719",
      "title": "Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2013-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01014208",
      "title": "Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-08-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01078922",
      "title": "Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2014-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01195714",
      "title": "Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years",
      "status": "COMPLETED",
      "last_update": "2018-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01397591",
      "title": "Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2014-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01481272",
      "title": "Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2021-12-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01555541",
      "title": "Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01626352",
      "title": "Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2017-11-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02412267",
      "title": "Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2016-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ORELABRUTINIB": {
    "n": 19,
    "n_observational": 1,
    "n_active": 10,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05933967",
      "title": "A Study of Orelabrutinib Plus R-CHOP in Treatment-na\u00efve Patients With Double Expression Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2023-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06647940",
      "title": "Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients\uff08Rocket Trial\uff09",
      "status": "RECRUITING",
      "last_update": "2024-10-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06701357",
      "title": "CR-CHOP+X in Previously Untreated DEL",
      "status": "RECRUITING",
      "last_update": "2024-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07072208",
      "title": "Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-07-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07078500",
      "title": "Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07499271",
      "title": "Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation",
      "status": "RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07680933",
      "title": "Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07778212",
      "title": "Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05097443",
      "title": "Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05234684",
      "title": "A Study of Orelabrutinib Plus R-CHOP in Treatment-na\u00efve Patients With MCD Subtype Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2024-02-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05351346",
      "title": "Genotype-guided Treatment in DLBCL",
      "status": "UNKNOWN",
      "last_update": "2023-03-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05381506",
      "title": "Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2022-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05498259",
      "title": "Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL",
      "status": "UNKNOWN",
      "last_update": "2023-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05784987",
      "title": "R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-27",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05809180",
      "title": "Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients",
      "status": "UNKNOWN",
      "last_update": "2023-04-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06290817",
      "title": "Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI",
      "status": "UNKNOWN",
      "last_update": "2024-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06516978",
      "title": "A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06530511",
      "title": "Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL",
      "status": "UNKNOWN",
      "last_update": "2025-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07677813",
      "title": "Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PIRTOBRUTINIB": {
    "n": 11,
    "n_observational": 0,
    "n_active": 9,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05990465",
      "title": "LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07255963",
      "title": "Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-12-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04849416",
      "title": "A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)",
      "status": "COMPLETED",
      "last_update": "2026-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07122609",
      "title": "Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07220187",
      "title": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07744724",
      "title": "Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07744737",
      "title": "Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07744750",
      "title": "Pirtobrutinib+Sonrotoclax\uff08PS) Regimen in the Treatment of B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07812493",
      "title": "Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "POLATUZUMAB VEDOTIN": {
    "n": 66,
    "n_observational": 5,
    "n_active": 46,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT04332822",
      "title": "A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04491370",
      "title": "Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04844866",
      "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05633615",
      "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05800366",
      "title": "A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06015880",
      "title": "Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06050694",
      "title": "Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)",
      "status": "RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06176729",
      "title": "Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients",
      "status": "RECRUITING",
      "last_update": "2023-12-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06522555",
      "title": "The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-08-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06554600",
      "title": "A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06594939",
      "title": "Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06664411",
      "title": "Pola-ZR2P in Previously Untreated DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06765317",
      "title": "A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06803693",
      "title": "Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06890884",
      "title": "A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07001540",
      "title": "Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation",
      "status": "RECRUITING",
      "last_update": "2025-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07072208",
      "title": "Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-07-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07397832",
      "title": "CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07499271",
      "title": "Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation",
      "status": "RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07608978",
      "title": "Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes",
      "status": "RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07654426",
      "title": "The CARDIOPROTECT Trial",
      "status": "RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07680933",
      "title": "Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07778212",
      "title": "Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01691898",
      "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)",
      "status": "COMPLETED",
      "last_update": "2020-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02257567",
      "title": "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-11-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02600897",
      "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-12-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02611323",
      "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-10-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02729896",
      "title": "A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2020-12-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03274492",
      "title": "A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-05-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03467373",
      "title": "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL",
      "status": "COMPLETED",
      "last_update": "2025-01-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03677154",
      "title": "Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04182204",
      "title": "A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-12-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04231877",
      "title": "Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04236141",
      "title": "A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).",
      "status": "TERMINATED",
      "last_update": "2023-03-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04323956",
      "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04479267",
      "title": "Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04535102",
      "title": "POLA+BR for Relapsed or Refractory DLBCL",
      "status": "WITHDRAWN",
      "last_update": "2022-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04607772",
      "title": "Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "WITHDRAWN",
      "last_update": "2025-10-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665765",
      "title": "Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04739813",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04790903",
      "title": "A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2024-07-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04833114",
      "title": "Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2026-06-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04914741",
      "title": "A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)",
      "status": "UNKNOWN",
      "last_update": "2024-08-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05455697",
      "title": "Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05498220",
      "title": "Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05798156",
      "title": "Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05940051",
      "title": "Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05940064",
      "title": "Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05966233",
      "title": "R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2024-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06441097",
      "title": "Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06516978",
      "title": "A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06530511",
      "title": "Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL",
      "status": "UNKNOWN",
      "last_update": "2025-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06665217",
      "title": "G-Pola-ZLP in Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07012980",
      "title": "Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07034508",
      "title": "A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07122609",
      "title": "Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231250",
      "title": "Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07398638",
      "title": "Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07415980",
      "title": "Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07502872",
      "title": "TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07677813",
      "title": "Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07702851",
      "title": "A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07714421",
      "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07744724",
      "title": "Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07812493",
      "title": "Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "POSELTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05335018",
      "title": "GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07269639",
      "title": "Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RITUXIMAB": {
    "n": 185,
    "n_observational": 15,
    "n_active": 42,
    "n_withdrawn": 5,
    "trials": [
     {
      "nct": "NCT04844866",
      "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05257018",
      "title": "R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05389423",
      "title": "Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05518383",
      "title": "B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021",
      "status": "RECRUITING",
      "last_update": "2022-08-26",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06050694",
      "title": "Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)",
      "status": "RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06091865",
      "title": "A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06244368",
      "title": "GVM\u00b1R in Patients With Relapsed or Refractory Aggressive NHL.",
      "status": "RECRUITING",
      "last_update": "2025-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06683885",
      "title": "A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-11-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06693830",
      "title": "ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-01-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06742502",
      "title": "Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL",
      "status": "RECRUITING",
      "last_update": "2025-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06765317",
      "title": "A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06829771",
      "title": "Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06905509",
      "title": "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06929624",
      "title": "A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07001540",
      "title": "Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation",
      "status": "RECRUITING",
      "last_update": "2025-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07189065",
      "title": "A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07255963",
      "title": "Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-12-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493148",
      "title": "Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07778212",
      "title": "Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00001337",
      "title": "Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003397",
      "title": "Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004112",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005089",
      "title": "S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00007852",
      "title": "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00017381",
      "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-01-09",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00022971",
      "title": "Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2019-12-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00049036",
      "title": "Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00052923",
      "title": "Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2009-02-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00052936",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00055640",
      "title": "Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2010-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00059904",
      "title": "Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-07-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00062296",
      "title": "Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00064116",
      "title": "Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-04-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00069966",
      "title": "Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse",
      "status": "UNKNOWN",
      "last_update": "2009-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00070018",
      "title": "S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-01-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00072514",
      "title": "Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073957",
      "title": "Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080925",
      "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2012-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00088881",
      "title": "Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2017-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101010",
      "title": "Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00107380",
      "title": "S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00118209",
      "title": "Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-11-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00135499",
      "title": "R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-08-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00144807",
      "title": "ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00151320",
      "title": "Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL",
      "status": "COMPLETED",
      "last_update": "2018-06-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00169169",
      "title": "Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2005-09-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00169195",
      "title": "Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00176475",
      "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",
      "status": "TERMINATED",
      "last_update": "2013-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00216164",
      "title": "Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2011-05-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00268853",
      "title": "A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin",
      "status": "COMPLETED",
      "last_update": "2024-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00274924",
      "title": "Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00290667",
      "title": "Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00355199",
      "title": "Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.",
      "status": "COMPLETED",
      "last_update": "2017-08-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00398372",
      "title": "Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment",
      "status": "COMPLETED",
      "last_update": "2011-06-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00400478",
      "title": "A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13",
      "status": "COMPLETED",
      "last_update": "2016-05-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00436280",
      "title": "Chemotherapy for Participants With Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00451178",
      "title": "A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only",
      "status": "COMPLETED",
      "last_update": "2020-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00536978",
      "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2020-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00553943",
      "title": "Phase II Study to Evaluate the Combination of Rituximab and DepoCyte\u00ae in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis",
      "status": "COMPLETED",
      "last_update": "2018-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00590941",
      "title": "Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-05-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00599170",
      "title": "Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00617929",
      "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00655837",
      "title": "Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL",
      "status": "COMPLETED",
      "last_update": "2014-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00691652",
      "title": "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-11-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00719472",
      "title": "A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)",
      "status": "COMPLETED",
      "last_update": "2017-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00736450",
      "title": "Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-10-24",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00765245",
      "title": "Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-04-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00785330",
      "title": "Allo-hNHL (FluBuCy)",
      "status": "COMPLETED",
      "last_update": "2020-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00790036",
      "title": "Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy",
      "status": "COMPLETED",
      "last_update": "2017-07-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00818961",
      "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2013-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00834951",
      "title": "Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2009-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00851552",
      "title": "Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment",
      "status": "TERMINATED",
      "last_update": "2014-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00867087",
      "title": "Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00980304",
      "title": "R Retreatment in 1st Relapsed DLBCL",
      "status": "UNKNOWN",
      "last_update": "2009-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00987493",
      "title": "Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00992446",
      "title": "Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01009970",
      "title": "Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet\u00ae), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2011-10-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01044745",
      "title": "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2023-09-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01144403",
      "title": "A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.",
      "status": "TERMINATED",
      "last_update": "2016-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01210287",
      "title": "Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP",
      "status": "UNKNOWN",
      "last_update": "2014-01-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01238692",
      "title": "A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01277172",
      "title": "TREatment of degeNerative and Neoplastic Diseases With Rituximab",
      "status": "UNKNOWN",
      "last_update": "2011-01-14",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01278602",
      "title": "R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2013-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01285765",
      "title": "Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients",
      "status": "COMPLETED",
      "last_update": "2020-07-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01434472",
      "title": "High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2021-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01448096",
      "title": "Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01510184",
      "title": "Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy",
      "status": "TERMINATED",
      "last_update": "2021-12-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01539174",
      "title": "Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01653067",
      "title": "STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01804127",
      "title": "Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL",
      "status": "UNKNOWN",
      "last_update": "2013-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01805557",
      "title": "Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.",
      "status": "COMPLETED",
      "last_update": "2022-06-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01842672",
      "title": "Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-10-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01855750",
      "title": "A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-02-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01914718",
      "title": "Dose-adjusted EPOCH-R in MYC Positive DLBCL",
      "status": "TERMINATED",
      "last_update": "2014-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01925612",
      "title": "Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2018-06-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01939327",
      "title": "Safety and Efficacy of Revlimid\u00ae (Lenalidomide) With Mabthera\u00ae (Rituximab) in Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01990144",
      "title": "Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL",
      "status": "UNKNOWN",
      "last_update": "2013-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02060656",
      "title": "Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)",
      "status": "UNKNOWN",
      "last_update": "2019-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02077166",
      "title": "Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02141451",
      "title": "ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL",
      "status": "COMPLETED",
      "last_update": "2020-02-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02168907",
      "title": "CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02205333",
      "title": "A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies",
      "status": "TERMINATED",
      "last_update": "2017-06-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02219737",
      "title": "Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02257567",
      "title": "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-11-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02285062",
      "title": "Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-06-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02329080",
      "title": "New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement",
      "status": "COMPLETED",
      "last_update": "2025-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02348216",
      "title": "Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02366663",
      "title": "BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin\u00ae)/BEAM With ASCT for Relapsed DLBCL",
      "status": "TERMINATED",
      "last_update": "2018-03-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02532192",
      "title": "A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02594163",
      "title": "Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-10-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02611323",
      "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-10-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02700022",
      "title": "A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas",
      "status": "TERMINATED",
      "last_update": "2017-11-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02734771",
      "title": "A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02747732",
      "title": "Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL",
      "status": "UNKNOWN",
      "last_update": "2019-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02752815",
      "title": "Reduced Chemotherapy in Low Risk DLBCL",
      "status": "UNKNOWN",
      "last_update": "2022-12-05",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02753647",
      "title": "Chidamide Plus R-CHOP in Elderly DLBCL",
      "status": "UNKNOWN",
      "last_update": "2017-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02758925",
      "title": "CyBeR Association in Relapsed/Refractory DLBCL",
      "status": "UNKNOWN",
      "last_update": "2016-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02772822",
      "title": "A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients",
      "status": "UNKNOWN",
      "last_update": "2016-05-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02842931",
      "title": "R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis",
      "status": "UNKNOWN",
      "last_update": "2016-07-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02867566",
      "title": "A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2020-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890602",
      "title": "Erythropoietin for Management of Anemia Caused by Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2020-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02951156",
      "title": "Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",
      "status": "TERMINATED",
      "last_update": "2020-12-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03019666",
      "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
      "status": "COMPLETED",
      "last_update": "2022-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03023878",
      "title": "Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03036904",
      "title": "Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2022-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03136497",
      "title": "A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03151044",
      "title": "R\u00b1CEOP90 Versus R\u00b1CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL",
      "status": "UNKNOWN",
      "last_update": "2017-05-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03200015",
      "title": "Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03201471",
      "title": "Chidamide With R-CHOP Regimen for DLBCL Patients",
      "status": "UNKNOWN",
      "last_update": "2018-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03244176",
      "title": "Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study",
      "status": "UNKNOWN",
      "last_update": "2024-07-30",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03259529",
      "title": "Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL",
      "status": "COMPLETED",
      "last_update": "2021-06-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03283202",
      "title": "Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors",
      "status": "COMPLETED",
      "last_update": "2021-04-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03399747",
      "title": "Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2018-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03467373",
      "title": "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL",
      "status": "COMPLETED",
      "last_update": "2025-01-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03485118",
      "title": "RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03513601",
      "title": "Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2018-05-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03579927",
      "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2020-01-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03650933",
      "title": "A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients",
      "status": "UNKNOWN",
      "last_update": "2024-02-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03704714",
      "title": "Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma",
      "status": "SUSPENDED",
      "last_update": "2022-08-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03736616",
      "title": "Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL",
      "status": "UNKNOWN",
      "last_update": "2022-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03777085",
      "title": "Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "UNKNOWN",
      "last_update": "2019-05-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03795571",
      "title": "Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL",
      "status": "UNKNOWN",
      "last_update": "2019-02-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03864419",
      "title": "Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda",
      "status": "TERMINATED",
      "last_update": "2024-01-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03943901",
      "title": "Split-Dose R-CHOP for Older Adults With DLBCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03984448",
      "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03995147",
      "title": "Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04022005",
      "title": "Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL",
      "status": "COMPLETED",
      "last_update": "2023-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04049825",
      "title": "A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL",
      "status": "COMPLETED",
      "last_update": "2026-04-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04164368",
      "title": "Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2024-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04214444",
      "title": "Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab",
      "status": "COMPLETED",
      "last_update": "2026-02-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04279938",
      "title": "A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL",
      "status": "WITHDRAWN",
      "last_update": "2020-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04361279",
      "title": "A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL",
      "status": "COMPLETED",
      "last_update": "2023-12-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04404283",
      "title": "Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04436107",
      "title": "Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04442022",
      "title": "A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04517435",
      "title": "ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-02-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04546620",
      "title": "Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04659434",
      "title": "Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL",
      "status": "UNKNOWN",
      "last_update": "2020-12-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665765",
      "title": "Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04833114",
      "title": "Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2026-06-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04974996",
      "title": "A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)",
      "status": "WITHDRAWN",
      "last_update": "2022-03-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04978584",
      "title": "Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05115409",
      "title": "Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)",
      "status": "UNKNOWN",
      "last_update": "2022-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05179733",
      "title": "The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years",
      "status": "UNKNOWN",
      "last_update": "2023-05-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05189197",
      "title": "A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression",
      "status": "UNKNOWN",
      "last_update": "2024-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05280626",
      "title": "First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-03-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05428670",
      "title": "The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.",
      "status": "UNKNOWN",
      "last_update": "2022-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05575973",
      "title": "Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2022-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05777369",
      "title": "R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05798156",
      "title": "Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05940051",
      "title": "Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06062641",
      "title": "Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06508658",
      "title": "A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06516978",
      "title": "A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06530511",
      "title": "Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL",
      "status": "UNKNOWN",
      "last_update": "2025-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06890585",
      "title": "Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06925555",
      "title": "Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07034508",
      "title": "A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07159906",
      "title": "Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07220187",
      "title": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07269639",
      "title": "Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07649304",
      "title": "AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The \"Glofit-RCHOP Study\")",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07744737",
      "title": "Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07764601",
      "title": "R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SPEBRUTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02031419",
      "title": "Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TAFASITAMAB": {
    "n": 22,
    "n_observational": 7,
    "n_active": 15,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT05552937",
      "title": "Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL",
      "status": "RECRUITING",
      "last_update": "2022-09-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05890352",
      "title": "Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment",
      "status": "RECRUITING",
      "last_update": "2025-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06521255",
      "title": "Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-07-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07126236",
      "title": "Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07225439",
      "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02399085",
      "title": "Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL",
      "status": "COMPLETED",
      "last_update": "2023-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02763319",
      "title": "A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2025-07-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04134936",
      "title": "Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL",
      "status": "COMPLETED",
      "last_update": "2024-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04607772",
      "title": "Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "WITHDRAWN",
      "last_update": "2025-10-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04661007",
      "title": "To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04824092",
      "title": "Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04974216",
      "title": "Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04978584",
      "title": "Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05222555",
      "title": "Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05328102",
      "title": "Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2024-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429268",
      "title": "Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05455697",
      "title": "Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05626322",
      "title": "Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-09-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05821088",
      "title": "Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07030699",
      "title": "A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07502872",
      "title": "TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07621406",
      "title": "Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TAZEMETOSTAT": {
    "n": 12,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05890352",
      "title": "Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment",
      "status": "RECRUITING",
      "last_update": "2025-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01897571",
      "title": "Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL",
      "status": "COMPLETED",
      "last_update": "2024-03-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02220842",
      "title": "A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-01-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02875548",
      "title": "A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study",
      "status": "COMPLETED",
      "last_update": "2025-11-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02889523",
      "title": "Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03010982",
      "title": "Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-03-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03028103",
      "title": "Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients",
      "status": "COMPLETED",
      "last_update": "2023-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03456726",
      "title": "Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation",
      "status": "COMPLETED",
      "last_update": "2022-12-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04537715",
      "title": "Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels",
      "status": "COMPLETED",
      "last_update": "2025-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05618366",
      "title": "Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-04-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05627245",
      "title": "Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05934838",
      "title": "A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TIRABRUTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TISAGENLECLEUCEL": {
    "n": 15,
    "n_observational": 6,
    "n_active": 4,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT04094311",
      "title": "Study of Out of Specification for Tisagenlecleucel",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05633615",
      "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02445248",
      "title": "Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients",
      "status": "COMPLETED",
      "last_update": "2024-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03570892",
      "title": "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-06-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03610724",
      "title": "Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2024-06-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03630159",
      "title": "Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2022-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03876028",
      "title": "Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients",
      "status": "TERMINATED",
      "last_update": "2023-01-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04456023",
      "title": "Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)",
      "status": "WITHDRAWN",
      "last_update": "2022-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04726787",
      "title": "RadiothErapy priMIng for CAR-T",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-09",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04855253",
      "title": "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL",
      "status": "SUSPENDED",
      "last_update": "2026-01-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04890236",
      "title": "Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study",
      "status": "COMPLETED",
      "last_update": "2025-01-20",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05075603",
      "title": "Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy",
      "status": "COMPLETED",
      "last_update": "2026-08-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05199961",
      "title": "Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel",
      "status": "TERMINATED",
      "last_update": "2023-05-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06003179",
      "title": "Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah",
      "status": "WITHDRAWN",
      "last_update": "2024-11-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07676877",
      "title": "Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TOSITUMOMAB": {
    "n": 9,
    "n_observational": 2,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00006695",
      "title": "Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00022932",
      "title": "Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP",
      "status": "UNKNOWN",
      "last_update": "2005-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073918",
      "title": "Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073931",
      "title": "Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00107380",
      "title": "S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110071",
      "title": "Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00329030",
      "title": "Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)",
      "status": "COMPLETED",
      "last_update": "2021-11-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00490009",
      "title": "Phase 2 Study of Bexxar in Relapsed/Refractory DLCL",
      "status": "COMPLETED",
      "last_update": "2017-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01868035",
      "title": "Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP",
      "status": "COMPLETED",
      "last_update": "2017-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TOSITUMOMAB 131I": {
    "n": 0,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": []
   },
   "UBLITUXIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02793583",
      "title": "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma",
      "status": "TERMINATED",
      "last_update": "2022-07-21",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VECABRUTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03037645",
      "title": "Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers",
      "status": "TERMINATED",
      "last_update": "2020-10-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VELTUZUMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00596804",
      "title": "Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01101581",
      "title": "Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL",
      "status": "WITHDRAWN",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VENETOCLAX": {
    "n": 35,
    "n_observational": 1,
    "n_active": 11,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT03223610",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06649812",
      "title": "Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01742988",
      "title": "Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02611323",
      "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "COMPLETED",
      "last_update": "2023-10-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02987400",
      "title": "Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL",
      "status": "COMPLETED",
      "last_update": "2022-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02992522",
      "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03036904",
      "title": "Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2022-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03064867",
      "title": "Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2022-11-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03082209",
      "title": "A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-12-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03135262",
      "title": "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2021-12-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03136497",
      "title": "A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03255096",
      "title": "A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6",
      "status": "COMPLETED",
      "last_update": "2022-01-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03276468",
      "title": "Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas",
      "status": "COMPLETED",
      "last_update": "2023-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03357627",
      "title": "A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-02-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03530683",
      "title": "A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma",
      "status": "TERMINATED",
      "last_update": "2024-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03547115",
      "title": "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML",
      "status": "TERMINATED",
      "last_update": "2026-03-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03583424",
      "title": "Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03797261",
      "title": "A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies",
      "status": "TERMINATED",
      "last_update": "2021-12-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03886649",
      "title": "Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.",
      "status": "TERMINATED",
      "last_update": "2022-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03955783",
      "title": "Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-10-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03984448",
      "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04285268",
      "title": "Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2026-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04572763",
      "title": "Copanlisib Plus Venetoclax in R/R DLBCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04607772",
      "title": "Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "WITHDRAWN",
      "last_update": "2025-10-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04739813",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04790903",
      "title": "A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)",
      "status": "TERMINATED",
      "last_update": "2024-07-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05211336",
      "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05618366",
      "title": "Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-04-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665530",
      "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05753501",
      "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05863845",
      "title": "Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL",
      "status": "UNKNOWN",
      "last_update": "2023-05-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06247540",
      "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2024-02-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06516978",
      "title": "A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": {
    "n": 29,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00017381",
      "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-01-09",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031642",
      "title": "Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2023-12-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058292",
      "title": "Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058422",
      "title": "Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-11-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00062114",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00064246",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder",
      "status": "COMPLETED",
      "last_update": "2013-01-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00070018",
      "title": "S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-01-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073957",
      "title": "Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00088881",
      "title": "Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2017-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00119392",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00310128",
      "title": "Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00322218",
      "title": "Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.",
      "status": "TERMINATED",
      "last_update": "2022-01-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00386321",
      "title": "Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2010-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00392691",
      "title": "Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment",
      "status": "COMPLETED",
      "last_update": "2019-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00438880",
      "title": "Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00562978",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2021-06-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00577278",
      "title": "A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan",
      "status": "COMPLETED",
      "last_update": "2024-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00591630",
      "title": "Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2021-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00689169",
      "title": "Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00690560",
      "title": "Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00695409",
      "title": "Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00902525",
      "title": "Zevalin Twice in Aggressive Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2012-12-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01157988",
      "title": "90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2010-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01359592",
      "title": "S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01434472",
      "title": "High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2021-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01490723",
      "title": "Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)",
      "status": "COMPLETED",
      "last_update": "2020-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01510184",
      "title": "Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy",
      "status": "TERMINATED",
      "last_update": "2021-12-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01686165",
      "title": "Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL",
      "status": "COMPLETED",
      "last_update": "2018-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02366663",
      "title": "BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin\u00ae)/BEAM With ASCT for Relapsed DLBCL",
      "status": "TERMINATED",
      "last_update": "2018-03-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZANUBRUTINIB": {
    "n": 51,
    "n_observational": 0,
    "n_active": 26,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05348213",
      "title": "Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05873712",
      "title": "Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome",
      "status": "RECRUITING",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05890352",
      "title": "Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment",
      "status": "RECRUITING",
      "last_update": "2025-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06005870",
      "title": "Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06375733",
      "title": "A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06503263",
      "title": "Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL",
      "status": "RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06522555",
      "title": "The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-08-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06554600",
      "title": "A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06664411",
      "title": "Pola-ZR2P in Previously Untreated DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06735664",
      "title": "Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation",
      "status": "RECRUITING",
      "last_update": "2025-09-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06764017",
      "title": "CHiR Therapy for Elderly DLBCL Intolerant to Chemo",
      "status": "RECRUITING",
      "last_update": "2025-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06803693",
      "title": "Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL",
      "status": "RECRUITING",
      "last_update": "2025-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06846463",
      "title": "Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+",
      "status": "RECRUITING",
      "last_update": "2026-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859008",
      "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07371923",
      "title": "Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07608978",
      "title": "Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes",
      "status": "RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02914938",
      "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-05-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03145064",
      "title": "Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03520920",
      "title": "BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)",
      "status": "COMPLETED",
      "last_update": "2024-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04282018",
      "title": "Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab",
      "status": "COMPLETED",
      "last_update": "2026-02-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04436107",
      "title": "Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04460248",
      "title": "Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04668365",
      "title": "Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma",
      "status": "SUSPENDED",
      "last_update": "2025-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04705129",
      "title": "Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL",
      "status": "UNKNOWN",
      "last_update": "2021-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04835870",
      "title": "Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL",
      "status": "UNKNOWN",
      "last_update": "2022-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04850495",
      "title": "Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05068440",
      "title": "Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib",
      "status": "COMPLETED",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05164770",
      "title": "Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-12-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05179733",
      "title": "The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years",
      "status": "UNKNOWN",
      "last_update": "2023-05-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05189197",
      "title": "A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression",
      "status": "UNKNOWN",
      "last_update": "2024-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05200312",
      "title": "A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2022-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05202782",
      "title": "Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05290090",
      "title": "ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL",
      "status": "UNKNOWN",
      "last_update": "2023-10-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05290337",
      "title": "ZR-CHOP in DLBCL With Specific Gene Abnormality",
      "status": "UNKNOWN",
      "last_update": "2022-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05392257",
      "title": "Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial",
      "status": "UNKNOWN",
      "last_update": "2022-05-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05428670",
      "title": "The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.",
      "status": "UNKNOWN",
      "last_update": "2022-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05527912",
      "title": "A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy",
      "status": "UNKNOWN",
      "last_update": "2023-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05596097",
      "title": "Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission",
      "status": "UNKNOWN",
      "last_update": "2022-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665530",
      "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05887726",
      "title": "Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors",
      "status": "UNKNOWN",
      "last_update": "2023-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05940051",
      "title": "Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05940064",
      "title": "Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06033820",
      "title": "Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL",
      "status": "UNKNOWN",
      "last_update": "2024-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06594432",
      "title": "Molecular Subtype-Guided R-CHOP-MTX\u00b1Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06646211",
      "title": "High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-10-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06665217",
      "title": "G-Pola-ZLP in Diffuse Large B-Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06669143",
      "title": "Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-11-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06890585",
      "title": "Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07012980",
      "title": "Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}